Page last updated: 2024-10-31

mitoxantrone and Neoplasm Metastasis

mitoxantrone has been researched along with Neoplasm Metastasis in 143 studies

Mitoxantrone: An anthracenedione-derived antineoplastic agent.
mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.

Neoplasm Metastasis: The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.

Research Excerpts

ExcerptRelevanceReference
"Cabazitaxel significantly improves overall survival (OS) in men with metastatic castration-resistant prostate cancer (mCRPC) progressing during or after docetaxel, but is associated with a higher rate of grade ≥3 neutropenia compared with docetaxel."9.22Severe neutropenia during cabazitaxel treatment is associated with survival benefit in men with metastatic castration-resistant prostate cancer (mCRPC): A post-hoc analysis of the TROPIC phase III trial. ( de Bono, J; de Wit, R; Liewen, H; Meisel, A; Sartor, O; Stenner-Liewen, F; Vogt, DR; von Felten, S, 2016)
"The aim of the current study was to evaluate the antitumor activity and toxicity of continuous infusion of 5-fluorouracil, mitoxantrone, and cisplatin (FMP therapy) in chemotherapy-naive patients with metastatic hepatocellular carcinoma (HCC)."9.11A phase II trial of continuous infusion of 5-fluorouracil, mitoxantrone, and cisplatin for metastatic hepatocellular carcinoma. ( Ikeda, M; Morizane, C; Okusaka, T; Takezako, Y; Ueno, H, 2005)
"Doxetaxel (DCT) and mitoxantrone (MX) are highly active and potentially synergistic agents in the treatment of metastatic breast cancer (MBC)."9.10A phase II study of dose-dense docetaxel and mitoxantrone in the treatment of patients with high-risk metastatic breast cancer. ( Breidenbach, M; König, E; Kurbacher, C; Mallmann, P; Schwonzen, M, 2002)
"The purpose of this study was to determine the maximum-tolerated dose of gemcitabine plus mitoxantrone in women with metastatic breast cancer (MBC) and to evaluate activity and toxicity of this combination in a phase II trial."9.10Phase I/II study of gemcitabine plus mitoxantrone as salvage chemotherapy in metastatic breast cancer. ( Calabrese, P; Caporusso, L; Catino, A; Crucitta, E; D'Amico, C; De Lena, M; Guida, M; Latorre, A; Lorusso, V; Mazzei, A; Sambiasi, D; Schittulli, F; Silvestris, N, 2003)
"Early phase II evaluation of intravenous bolus mitoxantrone indicated objective response rates of 17 36% in patients with metastatic breast cancer."9.09Phase II study of mitoxantrone by 14-day continuous infusion with granulocyte colony-stimulating factor (GCSF) support in patients with metastatic breast cancer and limited prior therapy. ( Fraschini, G; Holmes, FA; Hortobagyi, GN; Pusztai, L, 1999)
"To define the maximum-tolerated dose (MTD) and the dose-limiting toxicities (DLTs) of docetaxel in combination with mitoxantrone in patients with metastatic breast cancer (MBC)."9.09Dose-escalation study of docetaxel in combination with mitoxantrone as first-line treatment in patients with metastatic breast cancer. ( Androulakis, N; Georgoulias, V; Hatzidaki, D; Kakolyris, S; Katsogridakis, K; Kotsakis, T; Kouroussis, C; Mavroudis, D; Samonis, G; Souglakos, J; Vardakis, N; Vlachonikolis, J, 1999)
"Fifty patients with stage IIIB and IV breast cancer entered a prospective study receiving combination chemotherapy consisting of mitoxantrone (8 mg/m2) on day 1, methotrexate (30 mg/m2) on day 1, vincristine (1 mg/m2) on day 2, and carboplatine (250 mg/m2) on day 2 (MIMOC), plus cyclical hormonotherapy with tamoxifen (20 mg daily, days 1-10) and megestrol acetate (160 mg daily, days 11-21)."9.09First-line treatment with mitoxantrone, methotrexate, vincristine, and carboplatine (MIMOC) plus cyclical hormonotherapy with tamoxifen and megestrol acetate in advanced breast cancer. ( Agelaki, S; Chalkiadakis, G; Georgoulias, V; Kakolyris, S; Kalbakis, K; Koukourakis, M; Samonis, G; Sanidas, E; Tsiftsis, D; Vlachonicolis, J, 1999)
"Paclitaxel and mitoxantrone are highly active agents in the treatment of advanced breast cancer (ABC)."9.09Dose intensification of mitoxantrone in combination with paclitaxel in advanced breast cancer: a phase II study. ( Acito, L; Angiona, S; Bilancia, D; Costanzo, FD; Fioriti, L; Gasperoni, S; Giustini, L; Manzione, L; Sdrobolini, A; Valenti, L, 1999)
"This study evaluated mitoxantrone and paclitaxel combination chemotherapy in the treatment of patients with metastatic breast cancer."9.09Mitoxantrone and paclitaxel combination chemotherapy in metastatic breast cancer. ( Campbell, M; Cantrell, J; Cartmell, A; Ghalie, R; Harvey, J; Modiano, M; Newcomb, T; Rubin, A; Schuster, M; Urba, W, 2001)
"Mitoxantrone (MTZ) and vinorelbine (VNR) have shown a good efficacy in advanced breast cancer."9.08Mitoxantrone plus vinorelbine with granulocyte-colony stimulating factor (G-CSF) support in advanced breast cancer patients. A dose and schedule finding study. ( Comella, G; Comella, P; Cremone, L; Della Volpe, N; Frasci, G; Imbriani, A; Persico, G; Salzano, F, 1995)
"Patients with metastatic breast cancer were randomly assigned to receive as second-line chemotherapy either MMM (mitomycin 8 mg/m2 day 1; mitoxantrone 8 mg/m2 days 1 and 22; methotrexate 35 mg/m2 days 1 and 22) alone or in combination with filgrastim (5 micrograms/kg s."9.08Prophylactic filgrastim (G-CSF) during mitomycin-C, mitoxantrone, and methotrexate (MMM) treatment for metastatic breast cancer. A randomized study. ( Blomqvist, C; Jantunen, I; Kellokumpu-Lehtinen, P; Maiche, A; Muhonen, T; Pertovaara, H; Pyrhönen, S; Voutilainen, L, 1996)
"From January 1992 to July 1993, 28 patients with metastatic breast cancer were entered in a phase II trial to assess the activity and toxicity of the combination of mitoxantrone, 5-fluoruracil, and leucovorin."9.08Salvage chemotherapy in metastatic breast cancer: an experience with the combination of mitoxantrone, 5-fluorouracil, and L-leucovorin. ( Anastasi, P; Basurto, C; Colozza, M; De Angelis, V; Giansanti, M; Gori, S; Ludovini, V; Mosconi, AM; Tonato, M, 1996)
"To assess efficacy and toxicity of less toxic analogs for advanced breast cancer in elderly women, we performed a phase II study using the combination mitoxantrone (MTZ)-vinorelbine (VNR)."9.08[A phase II study with mitoxantrone-vinorelbine association in the treatment of advanced breast cancer in elderly women]. ( Bugat, R; Caunes, N; Chevreau, C; Gladieff, L; Houyau, P; Martinez, M; Mihura, J; Roché, H, 1996)
"Forty chemotherapy naive patients with metastatic or locally advanced breast cancer were treated in a randomized trial comparing mitozantrone 14 mg/m2 with epirubicin 75 mg/m2 given intravenously at 3-weekly intervals."9.08Comparison of mitozantrone and epirubicin in advanced breast cancer. ( Chambers, EJ; Cook, AM; Rees, GJ, 1996)
"Paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) is a highly active single agent in the treatment of breast cancer."9.08Paclitaxel with mitoxantrone with or without 5-fluorouracil and high-dose leucovorin in the treatment of metastatic breast cancer. ( Greco, FA; Hainsworth, JD, 1997)
"In this phase II trial we have evaluated the activity and toxicity of a combination regimen containing mitoxantrone, L-leucovorin, and fluorouracil in patients with advanced breast cancer pretreated with anthracyclines."9.08Mitoxantrone, fluorouracil, and L-folinic acid in anthracycline-pretreated metastatic breast cancer patients. ( Acito, L; Bascioni, R; De Signoribus, G; Giorgi, F; Giuliodori, L; Giustini, L; Silva, RR; Testa, E, 1997)
"In a phase II study, we treated 35 women with metastatic breast cancer with the following regimen: mitoxantrone 12 mg/m2 i."9.07The use of mitoxantrone, 5-fluorouracil and high-dose leucovorin in the treatment of advanced breast cancer. ( Hainsworth, JD, 1993)
"Based upon the hypothesis that dipyridamole would potentiate the cytotoxicity of mitoxantrone and the combination of 5-fluorouracil (5-FU) and leukovorin, we performed a phase I/II trial of the combination of dipyridamole, 5-FU, leukovorin, and mitoxantrone in patients with metastatic breast cancer."9.07Phase I/II trial of dipyridamole, 5-fluorouracil, leukovorin, and mitoxantrone in metastatic breast cancer. ( Budd, GT; Bukowski, RM; Herzog, P, 1994)
"A phase II study to test the toxicity and the efficacy of a weekly combination of Mitoxantrone, 5-Fluorouracil and L-Leucovorin (MFL) was carried out in 43 patients with metastatic breast cancer."9.07Phase II study of weekly mitoxantrone, 5-fluorouracil, and leucovorin in metastatic breast cancer. ( Campora, E; Gardin, G; Giudici, S; Lanfranco, C; Merlini, L; Miglietta, L; Naso, C; Repetto, L; Testore, F; Venturino, A, 1994)
"Twenty-one patients with anthracycline-pretreated advanced breast cancer were treated with mitomycin C plus mitoxantrone (MM), 10 mg/m2, on day 1 of a 28-day cycle."9.07Mitomycin C and mitoxantrone in anthracycline-pretreated advanced breast cancer patients. A phase II study. ( Bianco, AR; Carlomagno, C; De Laurentiis, M; De Placido, S; Del Mastro, L; Gravina, A; Gridelli, C; Pagliarulo, C; Perrone, F, 1994)
"60 patients with metastatic breast cancer were entered in a phase II study using folinic acid, 5-fluorouracil bolus and infusion and mitoxantrone with or without cyclophosphamide."9.07Folinic acid, 5-fluorouracil bolus and infusion and mitoxantrone with or without cyclophosphamide in metastatic breast cancer. ( Beerblock, K; de Gramont, A; Demuynck, B; Guillot, T; Krulik, M; Louvet, C; Marpeau, L; Pigné, A; Soubrane, D; Varette, C, 1993)
"In a Phase I-II clinical trial, 19 ambulatory women with metastatic breast cancer were treated with a combination of mitoxantrone, 5-fluorouracil, and leucovorin (MFL)."9.07A phase I clinical trial of a combination of mitoxantrone, 5-fluorouracil, and high-dose leucovorin given on a day 1 and day 8 schedule to patients with metastatic breast cancer. ( Gomez, EG; Vogel, CL, 1994)
"Ninety-three evaluable patients with metastatic breast cancer previously treated with chemotherapy, received mitoxantrone as a single agent (14 mg/m2, by rapid intravenous infusion, once every 3 weeks)."9.07Second-line chemotherapy with mitoxantrone as a single agent in metastatic breast cancer. ( Ben-Baruch, N; Brufman, G; Haim, N; Sulkes, A, 1993)
"Fifty-five women with metastatic breast cancer were treated with carboplatin (CBDCA), 55 mg/m2 i."9.07Carboplatin (CBDCA), 5-fluorouracil (5-FU) and mitoxantrone (DHAD): an effective and well tolerated regimen for metastatic breast cancer. ( Gonzalez, FG; Herranz, P; Hidalgo, OF; Rebollo, J; Tangco, E; Vieitez, JM, 1992)
"A new combination of mitoxantrone, folinic acid (leucovorin), and infusional fluorouracil (5-FU) was administered to 57 previously treated patients with metastatic breast cancer to evaluate the response rate, response duration, and toxicity of this regimen."9.07Phase II study of mitoxantrone, leucovorin, and infusional fluorouracil for treatment of metastatic breast cancer. ( Allison, MA; Brooks, B; Jones, SE; Mennel, RG; Paulson, RS; Rea, B; Tilmann, K; Westrick, MA, 1991)
"Between September 1988 and August 1990, we treated 35 women with metastatic breast cancer with a novel regimen containing mitoxantrone, fluorouracil (5-FU), and high-dose leucovorin."9.07Mitoxantrone, fluorouracil, and high-dose leucovorin: an effective, well-tolerated regimen for metastatic breast cancer. ( Andrews, MB; Greco, FA; Hainsworth, JD; Johnson, DH, 1991)
"Three hundred twenty-five women with metastatic adenocarcinoma of the breast who had failed one prior chemotherapeutic regimen for advanced disease were randomized to receive 14 mg/m2 of mitoxantrone or 75 mg/m2 of doxorubicin intravenously (IV) every 3 weeks."9.06Randomized clinical trial comparing mitoxantrone with doxorubicin in previously treated patients with metastatic breast cancer. ( Allegra, JC; Bryan, S; Cartwright, K; Dukart, G; Henderson, IC; Henry, D; Wolff, S; Woodcock, T, 1989)
"Twenty-seven women with metastatic breast cancer were treated with mitoxantrone as a single agent, with the use of an intensive dose-escalating schedule."9.06Intensive single-agent mitoxantrone for metastatic breast cancer. ( Bhardwaj, S; Holland, JF; Jones, RB; Paciucci, PA; Shpall, EJ; Strashun, A; Wilfinger, CL, 1988)
"Ninety patients with breast cancer refractory to cyclophosphamide/fluorouracil/methotrexate (CMF) have been randomized in their treatment, receiving either doxorubicin or mitoxantrone."9.06A comparison of mitoxantrone and doxorubicin in breast cancer. ( Gochnour, D; Hoth, D; Neidhart, JA; Roach, R; Young, D, 1986)
"Fifty-five patients with newly diagnosed, estrogen receptor negative, metastatic breast cancer were entered in a trial of mitoxantrone, 10 mg/m2 intravenous (IV), cyclophosphamide, 500 mg/m2 IV, and 5-fluorouracil, 1000 mg/m2 IV, which were given on day 1 of a 21-day treatment interval."9.05Mitoxantrone, cyclophosphamide, and 5-fluorouracil in the treatment of hormonally unresponsive metastatic breast cancer. ( Blumenschein, GR; Buzdar, AU; Esparza, L; Holmes, FA; Hortobagyi, GN; Yap, HY, 1984)
"Trials establishing the safety and efficacy of single-agent vinorelbine (Navelbine; Burroughs Wellcome Co, Research Triangle Park, NC; Pierre Fabre Médicament, Paris, France) as first- and second-line chemotherapy for metastatic breast cancer led to testing of the combination of vinorelbine and mitoxantrone."8.79Combination chemotherapy with vinorelbine (Navelbine) and mitoxantrone for metastatic breast cancer: a review. ( Vogel, CL, 1995)
"Most breast cancers (BCs) express estrogen receptor α (ERα) and are treated with the endocrine therapy (ET) drugs 4OH-tamoxifen (Tam) and fulvestrant (ICI 182,780; ICI)."7.88In silico screening for ERα down modulators identifies thioridazine as an anti-proliferative agent in primary, 4OH-tamoxifen-resistant and Y537S ERα-expressing breast cancer cells. ( Acconcia, F; Bianchi, F; Busonero, C; Leone, S, 2018)
"We treated 39 women with newly diagnosed stage IV breast cancer with a new regimen of mitoxantrone 18 mg/m2 on days 1, 29, 57, vincristine 1."7.68Mitoxantrone, vincristine, and 5-fluorouracil with leucovorin modulation as induction chemotherapy prior to high-dose intensification in metastatic breast cancer. ( Bitran, JD; Huffman, S; Mick, R; Myers, SE; Williams, SF, 1993)
"Mitoxantrone (DHAD), an anthracenedione with antineoplastic properties similar to doxorubicin, was tested for therapeutic efficacy and for immunomodulating action on lymphocyte subsets in 16 metastatic breast cancer patients, 12 of whom had been previously treated with chemotherapy."7.68Mitoxantrone as a single agent in pretreated metastatic breast cancer: effects on T lymphocyte subsets and their relation to clinical response. ( Archili, C; Barni, S; Cattaneo, G; Crispino, S; Lissoni, P; Paolorossi, F; Rescaldani, R; Tancini, G, 1991)
"Eleven patients (pts) with advanced refractory breast carcinoma were treated with combination chemotherapy (Planovin) including mitoxantrone 10 mg/m2 on day 1, cisplatin 60 mg/m2 on days 1-2, methotrexate 200 mg/m2 on day 15, vincristine 2 mg on day 15, leucovorin 15 mg/m2 on days 15-16 every 3 weeks."7.68Intensive chemotherapy with cisplatin, mitoxantrone, methotrexate and vincristine in metastatic breast cancer. ( Gardin, G; Guido, T; Miglietta, L; Pronzato, P; Queirolo, P; Repetto, L; Rosso, R, 1991)
"To further improve the effect of high-dose chemotherapy in the treatment of locally advanced and metastatic breast cancer, we sought to develop a second active high-dose noncross-resistant regimen to use in tandem with our customary high-dose regimen of cyclophosphamide, etoposide, and cisplatin (CVP)."7.68A phase II study of mitoxantrone, etoposide, and thiotepa with autologous marrow support for patients with relapsed breast cancer. ( Buzdar, A; Dunphy, F; Ewer, M; Holmes, F; Hortobagyi, G; Huan, S; Spitzer, G; Theriault, R; Wallerstein, R; Yau, J, 1990)
"Thirty-three patients with metastatic breast cancer received 135 cycles of chemotherapy consisting of mitoxantrone, methotrexate and chlorambucil."7.68Mitoxantrone, methotrexate and chlorambucil in metastatic breast cancer, a combination with relatively low subjective toxicity. ( Burghouts, JT, 1990)
"A total of 134 patients with advanced breast cancer and no prior chemotherapy for advanced disease were treated with mitoxantrone, 14 mg/m2 intravenously every 3 weeks."7.67Mitoxantrone as first-line chemotherapy for advanced breast cancer: results of a European collaborative study. ( Coleman, RE; Cornbleet, MA; McDonald, M; Mouridsen, HT; Rainer, H; Rubens, RD; Smith, IE; Smyth, JF; Stuart-Harris, RC; van Oosterom, AT, 1984)
"A total of 56 heavily pretreated patients with advanced breast cancer were treated with the combination mitomycin and mitoxantrone."7.67Mitomycin and mitoxantrone in previously treated patients with advanced breast cancer. ( Bishop, JF; Burns, I; Coates, A; Hillcoat, BL; Jeal, PN; Raghavan, D; Tattersall, MN; Woods, R, 1987)
"Fifty-two patients with hormonally unresponsive or estrogen receptor negative metastatic breast cancer who had not received prior chemotherapy received mitoxantrone 10 mg/m2, cyclophosphamide 500 mg/m2, and 5-fluorouracil 1000 mg/m2 (MCF) by short intravenous infusion every 21 days."7.67Mitoxantrone, cyclophosphamide, and fluorouracil in metastatic breast cancer unresponsive to hormonal therapy. ( Blumenschein, GR; Buzdar, AU; Esparza, L; Holmes, FA; Hortobagyi, GN; Hug, V; Yap, HY, 1987)
"A total of 39 women with metastatic breast cancer entered a pilot phase II study of the vindesine-mitoxantrone-mitomycin (VMMc) combination chemotherapy."7.67Long duration of response with vindesine-mitoxantrone-mitomycin (VMMc) combination chemotherapy in metastatic breast cancer: a pilot phase II study. ( Belpomme, D; Cour, V; George, C; Gisselbrecht, C; Heritier, F; Le Rol, A; Maral, J; Marty, M; Michaud, G, 1987)
"Three first-line combination chemotherapy regimens which included mitoxantrone were studied for the treatment of advanced breast cancer."7.67Use of mitoxantrone-based combination chemotherapy regimens as first-line treatment for advanced breast cancer. ( Bezwoda, WR; Dansey, RD; Hesdorffer, CS, 1987)
"A phase II study of mitoxantrone in cases of advanced breast cancer was conducted by a cooperative study group involving 7 institutions."7.67[Phase II study of mitoxantrone in advanced breast cancer]. ( Hoshino, A; Kubo, K; Nomura, Y; Ogawa, M; Ota, K; Taguchi, T; Tominaga, T; Yoshida, M, 1986)
"Results of first-line mitoxantrone chemotherapy for advanced breast cancer are presented."7.67First-line mitoxantrone chemotherapy for advanced breast cancer. ( Paterson, AH; Wilson, KS, 1986)
"The new anthracendione mitoxantrone, an anthraquinone derivate with structural similarities to doxorubicin (adriamycin) is active in the treatment of patients with metastatic breast cancer."7.67[Mitoxantrone in a combination regimen in advanced breast cancer]. ( Hausmaninger, H, 1985)
"124 patients with metastatic breast cancer were entered into this phase II trial of mitoxantrone (DHAD)."7.66Mitoxantrone in advanced breast cancer: a phase II trial of the Southwest Oncology Group. ( Fabian, C; Jones, SE; Knight, WA; Neidhart, JA; Tranum, BL; Von Hoff, DD, 1983)
"Treatment with cabazitaxel was prognostic for survival ≥2 years."6.78Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial. ( Bahl, A; de Bono, JS; Devin, J; Gravis, G; Hansen, S; Kocak, I; Oudard, S; Ozgüroglu, M; Sartor, AO; Shen, L; Tombal, B, 2013)
"Two hundred ten patients with primary breast cancer (T1-T4, N0, N1-2) were randomised to receive treatment with neoadjuvant chemoendocrine therapy or conventional post-operative chemoendocrine therapy."6.70Estrogen-receptor-directed neoadjuvant therapy for breast cancer: results of a randomised trial using formestane and methotrexate, mitozantrone and mitomycin C (MMM) chemotherapy. ( Coombes, RC; Ford, HT; Gazet, JC; Gray, R; Lowndes, S; Makinde, V; McConkey, C; Quilliam, J; Sutcliffe, R, 2001)
" No apparent dose-response relationship was observed in our study."6.69Phase I/II trial of high dose mitoxantrone in metastatic breast cancer: the M.D. Anderson Cancer Center experience. ( Buzdar, AU; Cristofanilli, M; Esparza, L; Holmes, FA; Hortobagyi, GN; Neidhart, JA; Valero, V, 1999)
"Advanced breast cancer remains a major clinical problem."6.68A phase II trial of mitoxantrone plus cyclophosphamide and 5-fluorouracil in modulation with levo-folinate for advanced breast cancer patients. ( Leonardi, V; Meli, M; Palmeri, S; Peralta, S; Rausa, L; Rini, GB; Russo, A, 1995)
"Of the 21 patients who had carcinoid tumours, 11 were previously untreated and two achieved a response (18%, 95% CI = 2-52%)."6.68Mitoxantrone in metastatic apudomas: a phase II study of the EORTC Gastro-Intestinal Cancer Cooperative Group. ( Lacave, AJ; Lips, CJ; Neijt, JP; Sahmoud, T; Splinter, TA; Taal, BG; Veenhof, CH, 1995)
"24 patients with advanced breast cancer entered the study: 16 aged 65-70 yrs, 4 patients 70-75 yrs, and 4 > 75 yrs."6.68Phase II study of mitoxantrone, 5-fluorouracil, and levo-leucovorin (MLF) in elderly advanced breast cancer patients. ( Caroti, C; Gallo, L; Mammoliti, S; Merlini, L, 1996)
"Sixty-one metastatic breast cancer patients with a mean age of 40 years were included."6.68Cyclophosphamide/mitoxantrone/melphalan (CMA) regimen prior to autologous bone marrow transplantation (ABMT) in metastatic breast cancer. ( Bremond, D; Delain, M; Devaux, Y; Extra, JM; Gisselbrecht, C; Guillevin, L; Herbrecht, R; Janvier, M; Lepage, E; Lotz, JP; Maraninchi, D; Peny, AM, 1996)
"All patients had advanced metastatic breast cancer and have been extensively pretreated with chemotherapy (28 patients), radiotherapy (13 patients), and hormonotherapy (24 patients)."6.68Treatment of advanced and relapsing breast cancer with a combination of paclitaxel and mitoxantrone. South-Central Hellenic Oncology Group. ( Panagos, GE, 1997)
"Patients with metastatic breast cancer refractory to all standard dose therapy were treated with escalating doses of mitoxantrone (45 to 105 mg/m2) and thiotepa (900 to 1,350 mg/m2) followed by autologous stem cell rescue."6.67Two novel high-dose treatment regimens for metastatic breast cancer--ifosfamide, carboplatin, plus etoposide and mitoxantrone plus thiotepa: outcomes and toxicities. ( Ballester, OF; Elfenbein, GJ; Fields, KK; Foody, MC; Hiemenz, JW; Janssen, WE; Kronish, LE; Perkins, JB; Zorsky, PE, 1993)
"182 patients with metastatic breast cancer were randomized to V (mg/m2 i."6.66Vindesine-mitoxantrone (VM) versus vindesine-4'-epidoxorubicin (VE) in metastatic breast cancer: a prospective randomized trial. ( Hausmaninger, H; Lehnert, M, 1988)
"Mitoxantrone appears to be an effective and well-tolerated agent for breast cancer."6.65A comparative trial of mitoxantrone and doxorubicin in patients with minimally pretreated breast cancer. ( Gochnour, D; Neidhart, JA; Roach, RW; Steinberg, JA; Young, D, 1984)
"All 11 patients had liver and/or lung metastases."5.28Anthracycline-carboplatin combination in metastatic breast cancer. ( Jungi, WF; Senn, HJ; Thürlimann, B, 1990)
"Cabazitaxel significantly improves overall survival (OS) in men with metastatic castration-resistant prostate cancer (mCRPC) progressing during or after docetaxel, but is associated with a higher rate of grade ≥3 neutropenia compared with docetaxel."5.22Severe neutropenia during cabazitaxel treatment is associated with survival benefit in men with metastatic castration-resistant prostate cancer (mCRPC): A post-hoc analysis of the TROPIC phase III trial. ( de Bono, J; de Wit, R; Liewen, H; Meisel, A; Sartor, O; Stenner-Liewen, F; Vogt, DR; von Felten, S, 2016)
"To investigate the use of docetaxel 75 mg/m(2) intravenously every 3 weeks plus prednisone 5 mg orally twice daily in men with metastatic hormone-refractory prostate cancer (HRPC) progressing after first-line mitoxantrone/prednisone (MP), the primary outcome being progression-free survival with prostatic-specific antigen (PSA) and pain response, toxicity and quality of life (QoL) also assessed."5.13The Canadian Uro-Oncology Group multicentre phase II study of docetaxel administered every 3 weeks with prednisone in men with metastatic hormone-refractory prostate cancer progressing after mitoxantrone/prednisone. ( Cheng, T; Ernst, S; Karakiewicz, P; North, S; Perrotte, P; Ruether, D; Saad, F; Winquist, E, 2008)
" To evaluate the efficacy and toxicity of biweekly docetaxel and mitoxantrone in patients with advanced breast cancer, the regimen consisting of docetaxel (60 mg/m), and mitoxantrone (8 mg/m) was administered intravenously to 59 patients every 2 weeks."5.13Biweekly docetaxel-containing chemotherapy may be the optimal schedule. ( Cai, Y; Hong, X; Hu, X; Li, J; Ou, Z; Shen, Z; Wang, Z; Yang, X; Zhao, X, 2008)
"The aim of the current study was to evaluate the antitumor activity and toxicity of continuous infusion of 5-fluorouracil, mitoxantrone, and cisplatin (FMP therapy) in chemotherapy-naive patients with metastatic hepatocellular carcinoma (HCC)."5.11A phase II trial of continuous infusion of 5-fluorouracil, mitoxantrone, and cisplatin for metastatic hepatocellular carcinoma. ( Ikeda, M; Morizane, C; Okusaka, T; Takezako, Y; Ueno, H, 2005)
"Doxetaxel (DCT) and mitoxantrone (MX) are highly active and potentially synergistic agents in the treatment of metastatic breast cancer (MBC)."5.10A phase II study of dose-dense docetaxel and mitoxantrone in the treatment of patients with high-risk metastatic breast cancer. ( Breidenbach, M; König, E; Kurbacher, C; Mallmann, P; Schwonzen, M, 2002)
"The purpose of this study was to determine the maximum-tolerated dose of gemcitabine plus mitoxantrone in women with metastatic breast cancer (MBC) and to evaluate activity and toxicity of this combination in a phase II trial."5.10Phase I/II study of gemcitabine plus mitoxantrone as salvage chemotherapy in metastatic breast cancer. ( Calabrese, P; Caporusso, L; Catino, A; Crucitta, E; D'Amico, C; De Lena, M; Guida, M; Latorre, A; Lorusso, V; Mazzei, A; Sambiasi, D; Schittulli, F; Silvestris, N, 2003)
"Early phase II evaluation of intravenous bolus mitoxantrone indicated objective response rates of 17 36% in patients with metastatic breast cancer."5.09Phase II study of mitoxantrone by 14-day continuous infusion with granulocyte colony-stimulating factor (GCSF) support in patients with metastatic breast cancer and limited prior therapy. ( Fraschini, G; Holmes, FA; Hortobagyi, GN; Pusztai, L, 1999)
"To define the maximum-tolerated dose (MTD) and the dose-limiting toxicities (DLTs) of docetaxel in combination with mitoxantrone in patients with metastatic breast cancer (MBC)."5.09Dose-escalation study of docetaxel in combination with mitoxantrone as first-line treatment in patients with metastatic breast cancer. ( Androulakis, N; Georgoulias, V; Hatzidaki, D; Kakolyris, S; Katsogridakis, K; Kotsakis, T; Kouroussis, C; Mavroudis, D; Samonis, G; Souglakos, J; Vardakis, N; Vlachonikolis, J, 1999)
"Fifty patients with stage IIIB and IV breast cancer entered a prospective study receiving combination chemotherapy consisting of mitoxantrone (8 mg/m2) on day 1, methotrexate (30 mg/m2) on day 1, vincristine (1 mg/m2) on day 2, and carboplatine (250 mg/m2) on day 2 (MIMOC), plus cyclical hormonotherapy with tamoxifen (20 mg daily, days 1-10) and megestrol acetate (160 mg daily, days 11-21)."5.09First-line treatment with mitoxantrone, methotrexate, vincristine, and carboplatine (MIMOC) plus cyclical hormonotherapy with tamoxifen and megestrol acetate in advanced breast cancer. ( Agelaki, S; Chalkiadakis, G; Georgoulias, V; Kakolyris, S; Kalbakis, K; Koukourakis, M; Samonis, G; Sanidas, E; Tsiftsis, D; Vlachonicolis, J, 1999)
"Paclitaxel and mitoxantrone are highly active agents in the treatment of advanced breast cancer (ABC)."5.09Dose intensification of mitoxantrone in combination with paclitaxel in advanced breast cancer: a phase II study. ( Acito, L; Angiona, S; Bilancia, D; Costanzo, FD; Fioriti, L; Gasperoni, S; Giustini, L; Manzione, L; Sdrobolini, A; Valenti, L, 1999)
"This study evaluated mitoxantrone and paclitaxel combination chemotherapy in the treatment of patients with metastatic breast cancer."5.09Mitoxantrone and paclitaxel combination chemotherapy in metastatic breast cancer. ( Campbell, M; Cantrell, J; Cartmell, A; Ghalie, R; Harvey, J; Modiano, M; Newcomb, T; Rubin, A; Schuster, M; Urba, W, 2001)
"Mitoxantrone (MTZ) and vinorelbine (VNR) have shown a good efficacy in advanced breast cancer."5.08Mitoxantrone plus vinorelbine with granulocyte-colony stimulating factor (G-CSF) support in advanced breast cancer patients. A dose and schedule finding study. ( Comella, G; Comella, P; Cremone, L; Della Volpe, N; Frasci, G; Imbriani, A; Persico, G; Salzano, F, 1995)
"A phase II trial was performed to assess the efficacy and toxicity of the combination mitoxantrone (MXN) and vinorelbine (VNR) as first-line chemotherapy for metastatic breast cancer."5.08[Combination of mitoxantrone-vinorelbine as first-line chemotherapy for metastatic breast carcinoma]. ( Ferrero, JM; François, E; Frenay, M; Hoch, M; Namer, M; Pivot, X; Teissier, E; Wendling, JL, 1995)
"Patients with metastatic breast cancer were randomly assigned to receive as second-line chemotherapy either MMM (mitomycin 8 mg/m2 day 1; mitoxantrone 8 mg/m2 days 1 and 22; methotrexate 35 mg/m2 days 1 and 22) alone or in combination with filgrastim (5 micrograms/kg s."5.08Prophylactic filgrastim (G-CSF) during mitomycin-C, mitoxantrone, and methotrexate (MMM) treatment for metastatic breast cancer. A randomized study. ( Blomqvist, C; Jantunen, I; Kellokumpu-Lehtinen, P; Maiche, A; Muhonen, T; Pertovaara, H; Pyrhönen, S; Voutilainen, L, 1996)
"From January 1992 to July 1993, 28 patients with metastatic breast cancer were entered in a phase II trial to assess the activity and toxicity of the combination of mitoxantrone, 5-fluoruracil, and leucovorin."5.08Salvage chemotherapy in metastatic breast cancer: an experience with the combination of mitoxantrone, 5-fluorouracil, and L-leucovorin. ( Anastasi, P; Basurto, C; Colozza, M; De Angelis, V; Giansanti, M; Gori, S; Ludovini, V; Mosconi, AM; Tonato, M, 1996)
"To assess efficacy and toxicity of less toxic analogs for advanced breast cancer in elderly women, we performed a phase II study using the combination mitoxantrone (MTZ)-vinorelbine (VNR)."5.08[A phase II study with mitoxantrone-vinorelbine association in the treatment of advanced breast cancer in elderly women]. ( Bugat, R; Caunes, N; Chevreau, C; Gladieff, L; Houyau, P; Martinez, M; Mihura, J; Roché, H, 1996)
"Forty chemotherapy naive patients with metastatic or locally advanced breast cancer were treated in a randomized trial comparing mitozantrone 14 mg/m2 with epirubicin 75 mg/m2 given intravenously at 3-weekly intervals."5.08Comparison of mitozantrone and epirubicin in advanced breast cancer. ( Chambers, EJ; Cook, AM; Rees, GJ, 1996)
"Paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) is a highly active single agent in the treatment of breast cancer."5.08Paclitaxel with mitoxantrone with or without 5-fluorouracil and high-dose leucovorin in the treatment of metastatic breast cancer. ( Greco, FA; Hainsworth, JD, 1997)
"In this phase II trial we have evaluated the activity and toxicity of a combination regimen containing mitoxantrone, L-leucovorin, and fluorouracil in patients with advanced breast cancer pretreated with anthracyclines."5.08Mitoxantrone, fluorouracil, and L-folinic acid in anthracycline-pretreated metastatic breast cancer patients. ( Acito, L; Bascioni, R; De Signoribus, G; Giorgi, F; Giuliodori, L; Giustini, L; Silva, RR; Testa, E, 1997)
"In a phase II study, we treated 35 women with metastatic breast cancer with the following regimen: mitoxantrone 12 mg/m2 i."5.07The use of mitoxantrone, 5-fluorouracil and high-dose leucovorin in the treatment of advanced breast cancer. ( Hainsworth, JD, 1993)
"Based upon the hypothesis that dipyridamole would potentiate the cytotoxicity of mitoxantrone and the combination of 5-fluorouracil (5-FU) and leukovorin, we performed a phase I/II trial of the combination of dipyridamole, 5-FU, leukovorin, and mitoxantrone in patients with metastatic breast cancer."5.07Phase I/II trial of dipyridamole, 5-fluorouracil, leukovorin, and mitoxantrone in metastatic breast cancer. ( Budd, GT; Bukowski, RM; Herzog, P, 1994)
"A phase II study to test the toxicity and the efficacy of a weekly combination of Mitoxantrone, 5-Fluorouracil and L-Leucovorin (MFL) was carried out in 43 patients with metastatic breast cancer."5.07Phase II study of weekly mitoxantrone, 5-fluorouracil, and leucovorin in metastatic breast cancer. ( Campora, E; Gardin, G; Giudici, S; Lanfranco, C; Merlini, L; Miglietta, L; Naso, C; Repetto, L; Testore, F; Venturino, A, 1994)
"Twenty-one patients with anthracycline-pretreated advanced breast cancer were treated with mitomycin C plus mitoxantrone (MM), 10 mg/m2, on day 1 of a 28-day cycle."5.07Mitomycin C and mitoxantrone in anthracycline-pretreated advanced breast cancer patients. A phase II study. ( Bianco, AR; Carlomagno, C; De Laurentiis, M; De Placido, S; Del Mastro, L; Gravina, A; Gridelli, C; Pagliarulo, C; Perrone, F, 1994)
"60 patients with metastatic breast cancer were entered in a phase II study using folinic acid, 5-fluorouracil bolus and infusion and mitoxantrone with or without cyclophosphamide."5.07Folinic acid, 5-fluorouracil bolus and infusion and mitoxantrone with or without cyclophosphamide in metastatic breast cancer. ( Beerblock, K; de Gramont, A; Demuynck, B; Guillot, T; Krulik, M; Louvet, C; Marpeau, L; Pigné, A; Soubrane, D; Varette, C, 1993)
"In a Phase I-II clinical trial, 19 ambulatory women with metastatic breast cancer were treated with a combination of mitoxantrone, 5-fluorouracil, and leucovorin (MFL)."5.07A phase I clinical trial of a combination of mitoxantrone, 5-fluorouracil, and high-dose leucovorin given on a day 1 and day 8 schedule to patients with metastatic breast cancer. ( Gomez, EG; Vogel, CL, 1994)
"Ninety-three evaluable patients with metastatic breast cancer previously treated with chemotherapy, received mitoxantrone as a single agent (14 mg/m2, by rapid intravenous infusion, once every 3 weeks)."5.07Second-line chemotherapy with mitoxantrone as a single agent in metastatic breast cancer. ( Ben-Baruch, N; Brufman, G; Haim, N; Sulkes, A, 1993)
"Fifty-five women with metastatic breast cancer were treated with carboplatin (CBDCA), 55 mg/m2 i."5.07Carboplatin (CBDCA), 5-fluorouracil (5-FU) and mitoxantrone (DHAD): an effective and well tolerated regimen for metastatic breast cancer. ( Gonzalez, FG; Herranz, P; Hidalgo, OF; Rebollo, J; Tangco, E; Vieitez, JM, 1992)
"A new combination of mitoxantrone, folinic acid (leucovorin), and infusional fluorouracil (5-FU) was administered to 57 previously treated patients with metastatic breast cancer to evaluate the response rate, response duration, and toxicity of this regimen."5.07Phase II study of mitoxantrone, leucovorin, and infusional fluorouracil for treatment of metastatic breast cancer. ( Allison, MA; Brooks, B; Jones, SE; Mennel, RG; Paulson, RS; Rea, B; Tilmann, K; Westrick, MA, 1991)
"Between September 1988 and August 1990, we treated 35 women with metastatic breast cancer with a novel regimen containing mitoxantrone, fluorouracil (5-FU), and high-dose leucovorin."5.07Mitoxantrone, fluorouracil, and high-dose leucovorin: an effective, well-tolerated regimen for metastatic breast cancer. ( Andrews, MB; Greco, FA; Hainsworth, JD; Johnson, DH, 1991)
"Three hundred twenty-five women with metastatic adenocarcinoma of the breast who had failed one prior chemotherapeutic regimen for advanced disease were randomized to receive 14 mg/m2 of mitoxantrone or 75 mg/m2 of doxorubicin intravenously (IV) every 3 weeks."5.06Randomized clinical trial comparing mitoxantrone with doxorubicin in previously treated patients with metastatic breast cancer. ( Allegra, JC; Bryan, S; Cartwright, K; Dukart, G; Henderson, IC; Henry, D; Wolff, S; Woodcock, T, 1989)
"Twenty-seven women with metastatic breast cancer were treated with mitoxantrone as a single agent, with the use of an intensive dose-escalating schedule."5.06Intensive single-agent mitoxantrone for metastatic breast cancer. ( Bhardwaj, S; Holland, JF; Jones, RB; Paciucci, PA; Shpall, EJ; Strashun, A; Wilfinger, CL, 1988)
"Ninety patients with breast cancer refractory to cyclophosphamide/fluorouracil/methotrexate (CMF) have been randomized in their treatment, receiving either doxorubicin or mitoxantrone."5.06A comparison of mitoxantrone and doxorubicin in breast cancer. ( Gochnour, D; Hoth, D; Neidhart, JA; Roach, R; Young, D, 1986)
"Fifty-five patients with newly diagnosed, estrogen receptor negative, metastatic breast cancer were entered in a trial of mitoxantrone, 10 mg/m2 intravenous (IV), cyclophosphamide, 500 mg/m2 IV, and 5-fluorouracil, 1000 mg/m2 IV, which were given on day 1 of a 21-day treatment interval."5.05Mitoxantrone, cyclophosphamide, and 5-fluorouracil in the treatment of hormonally unresponsive metastatic breast cancer. ( Blumenschein, GR; Buzdar, AU; Esparza, L; Holmes, FA; Hortobagyi, GN; Yap, HY, 1984)
"Trials establishing the safety and efficacy of single-agent vinorelbine (Navelbine; Burroughs Wellcome Co, Research Triangle Park, NC; Pierre Fabre Médicament, Paris, France) as first- and second-line chemotherapy for metastatic breast cancer led to testing of the combination of vinorelbine and mitoxantrone."4.79Combination chemotherapy with vinorelbine (Navelbine) and mitoxantrone for metastatic breast cancer: a review. ( Vogel, CL, 1995)
"Most breast cancers (BCs) express estrogen receptor α (ERα) and are treated with the endocrine therapy (ET) drugs 4OH-tamoxifen (Tam) and fulvestrant (ICI 182,780; ICI)."3.88In silico screening for ERα down modulators identifies thioridazine as an anti-proliferative agent in primary, 4OH-tamoxifen-resistant and Y537S ERα-expressing breast cancer cells. ( Acconcia, F; Bianchi, F; Busonero, C; Leone, S, 2018)
"Nineteen patients with metastatic breast cancer and six patients with refractory non-Hodgkin's lymphoma were initially treated with etoposide (VP-16) (2 gm/m2) and granulocyte-colony stimulating factor (G-CSF)."3.69Multiple cycles of high dose chemotherapy supported by hematopoietic progenitor cells as treatment for patients with advanced malignancies. ( Blume, KG; Chao, NJ; Hoyle, CF; Kusnierz-Glaz, CR; Long, GD; Negrin, RS; Schriber, JR, 1995)
"Fifty-three metastatic breast cancer patients were treated with a four-drug program of high-dose chemotherapy including cyclophosphamide (6 g/m2), thiotepa (500 mg/m2), carboplatin (800-1,600 mg/m2) and mitoxantrone (20-60 mg/m2) with autologous peripheral blood progenitor cell support followed by filgrastim."3.69[High-dose chemotherapy with four drugs and peripheral blood progenitor cell autologous transplantation in disseminated breast cancer]. ( Alonso, JL; Ayala, F; Casado, A; Díaz-Rubio, E; Llorente, L; López Martín, JA; Martín, M; Nieto, Y; Pérez Calvo, J; Pérez López, C; Rodríguez Lescure, A; Villegas, A, 1997)
"We treated 39 women with newly diagnosed stage IV breast cancer with a new regimen of mitoxantrone 18 mg/m2 on days 1, 29, 57, vincristine 1."3.68Mitoxantrone, vincristine, and 5-fluorouracil with leucovorin modulation as induction chemotherapy prior to high-dose intensification in metastatic breast cancer. ( Bitran, JD; Huffman, S; Mick, R; Myers, SE; Williams, SF, 1993)
"Mitoxantrone (DHAD), an anthracenedione with antineoplastic properties similar to doxorubicin, was tested for therapeutic efficacy and for immunomodulating action on lymphocyte subsets in 16 metastatic breast cancer patients, 12 of whom had been previously treated with chemotherapy."3.68Mitoxantrone as a single agent in pretreated metastatic breast cancer: effects on T lymphocyte subsets and their relation to clinical response. ( Archili, C; Barni, S; Cattaneo, G; Crispino, S; Lissoni, P; Paolorossi, F; Rescaldani, R; Tancini, G, 1991)
"Eleven patients (pts) with advanced refractory breast carcinoma were treated with combination chemotherapy (Planovin) including mitoxantrone 10 mg/m2 on day 1, cisplatin 60 mg/m2 on days 1-2, methotrexate 200 mg/m2 on day 15, vincristine 2 mg on day 15, leucovorin 15 mg/m2 on days 15-16 every 3 weeks."3.68Intensive chemotherapy with cisplatin, mitoxantrone, methotrexate and vincristine in metastatic breast cancer. ( Gardin, G; Guido, T; Miglietta, L; Pronzato, P; Queirolo, P; Repetto, L; Rosso, R, 1991)
"To further improve the effect of high-dose chemotherapy in the treatment of locally advanced and metastatic breast cancer, we sought to develop a second active high-dose noncross-resistant regimen to use in tandem with our customary high-dose regimen of cyclophosphamide, etoposide, and cisplatin (CVP)."3.68A phase II study of mitoxantrone, etoposide, and thiotepa with autologous marrow support for patients with relapsed breast cancer. ( Buzdar, A; Dunphy, F; Ewer, M; Holmes, F; Hortobagyi, G; Huan, S; Spitzer, G; Theriault, R; Wallerstein, R; Yau, J, 1990)
"Thirty-three patients with metastatic breast cancer received 135 cycles of chemotherapy consisting of mitoxantrone, methotrexate and chlorambucil."3.68Mitoxantrone, methotrexate and chlorambucil in metastatic breast cancer, a combination with relatively low subjective toxicity. ( Burghouts, JT, 1990)
"A total of 134 patients with advanced breast cancer and no prior chemotherapy for advanced disease were treated with mitoxantrone, 14 mg/m2 intravenously every 3 weeks."3.67Mitoxantrone as first-line chemotherapy for advanced breast cancer: results of a European collaborative study. ( Coleman, RE; Cornbleet, MA; McDonald, M; Mouridsen, HT; Rainer, H; Rubens, RD; Smith, IE; Smyth, JF; Stuart-Harris, RC; van Oosterom, AT, 1984)
"A total of 56 heavily pretreated patients with advanced breast cancer were treated with the combination mitomycin and mitoxantrone."3.67Mitomycin and mitoxantrone in previously treated patients with advanced breast cancer. ( Bishop, JF; Burns, I; Coates, A; Hillcoat, BL; Jeal, PN; Raghavan, D; Tattersall, MN; Woods, R, 1987)
"Fifty-two patients with hormonally unresponsive or estrogen receptor negative metastatic breast cancer who had not received prior chemotherapy received mitoxantrone 10 mg/m2, cyclophosphamide 500 mg/m2, and 5-fluorouracil 1000 mg/m2 (MCF) by short intravenous infusion every 21 days."3.67Mitoxantrone, cyclophosphamide, and fluorouracil in metastatic breast cancer unresponsive to hormonal therapy. ( Blumenschein, GR; Buzdar, AU; Esparza, L; Holmes, FA; Hortobagyi, GN; Hug, V; Yap, HY, 1987)
"A total of 39 women with metastatic breast cancer entered a pilot phase II study of the vindesine-mitoxantrone-mitomycin (VMMc) combination chemotherapy."3.67Long duration of response with vindesine-mitoxantrone-mitomycin (VMMc) combination chemotherapy in metastatic breast cancer: a pilot phase II study. ( Belpomme, D; Cour, V; George, C; Gisselbrecht, C; Heritier, F; Le Rol, A; Maral, J; Marty, M; Michaud, G, 1987)
"Three first-line combination chemotherapy regimens which included mitoxantrone were studied for the treatment of advanced breast cancer."3.67Use of mitoxantrone-based combination chemotherapy regimens as first-line treatment for advanced breast cancer. ( Bezwoda, WR; Dansey, RD; Hesdorffer, CS, 1987)
"A phase II study of mitoxantrone in cases of advanced breast cancer was conducted by a cooperative study group involving 7 institutions."3.67[Phase II study of mitoxantrone in advanced breast cancer]. ( Hoshino, A; Kubo, K; Nomura, Y; Ogawa, M; Ota, K; Taguchi, T; Tominaga, T; Yoshida, M, 1986)
"Results of first-line mitoxantrone chemotherapy for advanced breast cancer are presented."3.67First-line mitoxantrone chemotherapy for advanced breast cancer. ( Paterson, AH; Wilson, KS, 1986)
"The new anthracendione mitoxantrone, an anthraquinone derivate with structural similarities to doxorubicin (adriamycin) is active in the treatment of patients with metastatic breast cancer."3.67[Mitoxantrone in a combination regimen in advanced breast cancer]. ( Hausmaninger, H, 1985)
"124 patients with metastatic breast cancer were entered into this phase II trial of mitoxantrone (DHAD)."3.66Mitoxantrone in advanced breast cancer: a phase II trial of the Southwest Oncology Group. ( Fabian, C; Jones, SE; Knight, WA; Neidhart, JA; Tranum, BL; Von Hoff, DD, 1983)
"Treatment with cabazitaxel was prognostic for survival ≥2 years."2.78Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial. ( Bahl, A; de Bono, JS; Devin, J; Gravis, G; Hansen, S; Kocak, I; Oudard, S; Ozgüroglu, M; Sartor, AO; Shen, L; Tombal, B, 2013)
"These results suggest that the combination of ixabepilone and mitoxantrone is both feasible and active in castration-resistant prostate cancer and requires dosing with pegfilgrastim."2.76Ixabepilone, mitoxantrone, and prednisone for metastatic castration-resistant prostate cancer after docetaxel-based therapy: a phase 2 study of the Department Of Defense Prostate Cancer Clinical Trials Consortium. ( Beer, TM; Harzstark, AL; Liu, G; Pagliaro, LC; Rosenberg, JE; Ryan, CJ; Sharib, J; Small, EJ; Smith, DC; Weinberg, VK, 2011)
"Two hundred ten patients with primary breast cancer (T1-T4, N0, N1-2) were randomised to receive treatment with neoadjuvant chemoendocrine therapy or conventional post-operative chemoendocrine therapy."2.70Estrogen-receptor-directed neoadjuvant therapy for breast cancer: results of a randomised trial using formestane and methotrexate, mitozantrone and mitomycin C (MMM) chemotherapy. ( Coombes, RC; Ford, HT; Gazet, JC; Gray, R; Lowndes, S; Makinde, V; McConkey, C; Quilliam, J; Sutcliffe, R, 2001)
" Furthermore, we evaluated the times for hematopoietic reconstitution in a group of five BC patients in the high-risk adjuvant situation who underwent HD chemotherapy and hematopoietic rescue with positive/negative selected stem cells and compared it with our own data from 10 BC patients who, after identical HD therapy, received only positively selected CD34+ cells and 14 patients who, after identical HD therapy, received autografts purged by incubation with toxic ether lipids (ET-18-OCH3)."2.69Efficacy and safety of simultaneous immunomagnetic CD34+ cell selection and breast cancer cell purging in peripheral blood progenitor cell samples used for hematopoietic rescue after high-dose therapy. ( Berdel, WE; Cassens, U; Fietz, T; Hilgenfeld, E; Hoffmann, M; Hoppe, B; Kienast, J; Knauf, WU; Koenigsmann, M; Mohr, M; Sibrowski, W; Thiel, E, 1999)
" No apparent dose-response relationship was observed in our study."2.69Phase I/II trial of high dose mitoxantrone in metastatic breast cancer: the M.D. Anderson Cancer Center experience. ( Buzdar, AU; Cristofanilli, M; Esparza, L; Holmes, FA; Hortobagyi, GN; Neidhart, JA; Valero, V, 1999)
"Patients with localized prostate cancer receiving adjuvant chemotherapy had a higher initial objective response rate (95% vs 53%, P = 0."2.69Adjuvant mitozantrone chemotherapy in advanced prostate cancer. ( Halford, S; Lynch, M; Rigg, A; Roylance, R; Wang, J; Waxman, J, 2000)
"Advanced breast cancer remains a major clinical problem."2.68A phase II trial of mitoxantrone plus cyclophosphamide and 5-fluorouracil in modulation with levo-folinate for advanced breast cancer patients. ( Leonardi, V; Meli, M; Palmeri, S; Peralta, S; Rausa, L; Rini, GB; Russo, A, 1995)
"Of the 21 patients who had carcinoid tumours, 11 were previously untreated and two achieved a response (18%, 95% CI = 2-52%)."2.68Mitoxantrone in metastatic apudomas: a phase II study of the EORTC Gastro-Intestinal Cancer Cooperative Group. ( Lacave, AJ; Lips, CJ; Neijt, JP; Sahmoud, T; Splinter, TA; Taal, BG; Veenhof, CH, 1995)
"24 patients with advanced breast cancer entered the study: 16 aged 65-70 yrs, 4 patients 70-75 yrs, and 4 > 75 yrs."2.68Phase II study of mitoxantrone, 5-fluorouracil, and levo-leucovorin (MLF) in elderly advanced breast cancer patients. ( Caroti, C; Gallo, L; Mammoliti, S; Merlini, L, 1996)
" Dosage in subsequent cycles was adjusted according to hematologic toxicity."2.68A carboplatin-based regimen for the treatment of patients with advanced transitional cell carcinoma of the urothelium. ( Carroll, PR; Ernest, ML; Fippin, LJ; Small, EJ, 1996)
"Sixty-one metastatic breast cancer patients with a mean age of 40 years were included."2.68Cyclophosphamide/mitoxantrone/melphalan (CMA) regimen prior to autologous bone marrow transplantation (ABMT) in metastatic breast cancer. ( Bremond, D; Delain, M; Devaux, Y; Extra, JM; Gisselbrecht, C; Guillevin, L; Herbrecht, R; Janvier, M; Lepage, E; Lotz, JP; Maraninchi, D; Peny, AM, 1996)
"All patients had advanced metastatic breast cancer and have been extensively pretreated with chemotherapy (28 patients), radiotherapy (13 patients), and hormonotherapy (24 patients)."2.68Treatment of advanced and relapsing breast cancer with a combination of paclitaxel and mitoxantrone. South-Central Hellenic Oncology Group. ( Panagos, GE, 1997)
"Thirty-one patients with metastatic breast cancer treated on three successive high-dose chemotherapy and autologous bone marrow transplantation trials between January 1987 and March 1992 who achieved a complete response were evaluated."2.67Patterns of failure of complete responders following high-dose chemotherapy and autologous bone marrow transplantation for metastatic breast cancer: implications for the use of adjuvant radiation therapy. ( Halpern, H; Heimann, R; Mundt, AJ; Rubin, SJ; Sibley, GS; Weichselbaum, RR; Williams, S, 1994)
"Patients with metastatic breast cancer refractory to all standard dose therapy were treated with escalating doses of mitoxantrone (45 to 105 mg/m2) and thiotepa (900 to 1,350 mg/m2) followed by autologous stem cell rescue."2.67Two novel high-dose treatment regimens for metastatic breast cancer--ifosfamide, carboplatin, plus etoposide and mitoxantrone plus thiotepa: outcomes and toxicities. ( Ballester, OF; Elfenbein, GJ; Fields, KK; Foody, MC; Hiemenz, JW; Janssen, WE; Kronish, LE; Perkins, JB; Zorsky, PE, 1993)
"182 patients with metastatic breast cancer were randomized to V (mg/m2 i."2.66Vindesine-mitoxantrone (VM) versus vindesine-4'-epidoxorubicin (VE) in metastatic breast cancer: a prospective randomized trial. ( Hausmaninger, H; Lehnert, M, 1988)
"Mitoxantrone appears to be an effective and well-tolerated agent for breast cancer."2.65A comparative trial of mitoxantrone and doxorubicin in patients with minimally pretreated breast cancer. ( Gochnour, D; Neidhart, JA; Roach, RW; Steinberg, JA; Young, D, 1984)
"Abiraterone acetate has recently demonstrated a significant improvement in survival when compared to placebo in patients with docetaxel-treated mCRPC."2.47Role of second-line systemic treatment post-docetaxel in metastatic castrate resistant prostate cancer- current strategies and future directions. ( Alhasso, A; Ansari, A; Ansari, J; Glaholm, J; Hussain, SA; Mahmood, R, 2011)
"Treatment of hormone-refractory prostate cancer is palliative, and surgery and radiotherapy are used for the relief of lower urinary tract symptoms and localized painful bony metastases."2.43The changing pattern of management for hormone-refractory, metastatic prostate cancer. ( Bloomfield, D; James, ND; Luscombe, C, 2006)
" The pharmacokinetic parameters are described adequately by a three-compartment model with a terminal half-life of 71."2.38Pharmacokinetic and pharmacodynamic studies with mitoxantrone in the treatment of patients with nasopharyngeal carcinoma. ( Chang, SP; Chen, KY; Hu, OY; Jian, JM; Law, CK, 1992)
"Mitoxantrone is a DNA topoisomerase II poison commonly used for the treatment of hormone-refractory prostate cancer."1.34Mitoxantrone-related acute myeloblastic leukaemia in a patient with metastatic hormone-refractory prostate cancer. ( Bouscary, D; Dômont, J; Goldwasser, F; Martinez, V; Mir, O, 2007)
"Mitoxantrone is a minimally toxic chemotherapeutic agent, which justifies its current indication in hormone-resistant advanced prostate cancer."1.31[Value of mitoxantrone in metastatic hormone-resistant prostate cancer]. ( Dunet, F; Grise, P; Hellot, MF; Khalaf, A; Moussu, J; Pfister, C, 2002)
"All 11 patients had liver and/or lung metastases."1.28Anthracycline-carboplatin combination in metastatic breast cancer. ( Jungi, WF; Senn, HJ; Thürlimann, B, 1990)
"Mitoxantrone is a promising new agent developed in an attempt to find drugs with a broad spectrum of antitumor activity and devoid of cardiotoxicity."1.26Potential cardiotoxicity with mitoxantrone. ( Blumenschein, G; Bodey, G; Schell, FC; Valdivieso, M; Yap, HY, 1982)
"Thirty-one patients who had metastatic breast cancer extensively pretreated with combination chemotherapy, including doxorubicin, were tested with dihydroxyanthracenedione, 3 to 4 mg/m2 body surface area daily for 5 consecutive days every 4 weeks."1.26Dihydroxyanthracenedione: a promising new drug in the treatment of metastatic breast cancer. ( Blumenschein, GR; Bodey, GP; Buzdar, AU; Schell, FC; Valdivieso, M; Yap, HY, 1981)

Research

Studies (143)

TimeframeStudies, this research(%)All Research%
pre-199033 (23.08)18.7374
1990's58 (40.56)18.2507
2000's28 (19.58)29.6817
2010's23 (16.08)24.3611
2020's1 (0.70)2.80

Authors

AuthorsStudies
Li, Q1
Zhai, Y1
Luo, W1
Zhu, Z1
Zhang, X1
Xie, S1
Hong, C1
Wang, Y1
Su, Y1
Zhao, J1
Wang, C1
Zhou, S1
Shang, Q1
Ji, J1
Luan, Y1
Busonero, C1
Leone, S1
Bianchi, F1
Acconcia, F1
Grochtdreis, T1
König, HH1
Dobruschkin, A1
von Amsberg, G1
Dams, J1
Hakenberg, OW1
Perez-Gracia, JL2
Castellano, D1
Demkow, T1
Ali, T1
Caffo, O1
Heidenreich, A2
Schultze-Seemann, W1
Sautois, B1
Pavlik, I1
Qin, A1
Novosiadly, RD1
Shahir, A1
Ilaria, R1
Nippgen, J1
Halabi, S4
Dutta, S1
Tangen, CM1
Rosenthal, M1
Petrylak, DP1
Thompson, IM1
Chi, KN3
Araujo, JC1
Logothetis, C1
Quinn, DI1
Fizazi, K3
Morris, MJ1
Eisenberger, MA1
George, DJ2
De Bono, JS3
Higano, CS1
Tannock, IF3
Small, EJ4
Kelly, WK1
Lafrenie, RM1
Speigl, L1
Buckner, CA1
Pawelec, G1
Conlon, MS1
Shipp, C1
Aragon-Ching, JB1
Bahl, A2
Oudard, S3
Tombal, B1
Ozgüroglu, M1
Hansen, S1
Kocak, I1
Gravis, G1
Devin, J1
Shen, L1
Sartor, AO1
Harzstark, AL1
Rosenberg, JE1
Weinberg, VK1
Sharib, J1
Ryan, CJ1
Smith, DC1
Pagliaro, LC1
Beer, TM2
Liu, G1
Armstrong, AJ3
Sartor, O2
de Bono, J2
Kaplan, E1
Lin, CY1
Solomon, NC1
Joly, F1
Delva, R1
Mourey, L1
Sevin, E1
Bompas, E1
Vedrine, L1
Ravaud, A1
Eymard, JC1
Tubiana-Mathieu, N1
Linassier, C1
Houede, N1
Guillot, A1
Ringensen, F1
Cojocarasu, O1
Valenza, B1
Leconte, A1
Lheureux, S1
Clarisse, B1
Meisel, A1
von Felten, S1
Vogt, DR1
Liewen, H1
de Wit, R3
Stenner-Liewen, F1
Yu, P1
Diao, W1
Jiang, X1
Saad, F2
Ruether, D1
Ernst, S1
North, S2
Cheng, T1
Perrotte, P1
Karakiewicz, P1
Winquist, E2
Beardsley, EK1
Eisenberger, M2
DiPaola, RS1
Chen, YH1
Stein, M2
Vaughn, D1
Patrick-Miller, L1
Carducci, M1
Roth, B1
White, E1
Wilding, G1
Eton, DT1
Shevrin, DH1
Beaumont, J1
Victorson, D1
Cella, D1
Pinto, AC1
Ângelo, S1
Moreira, JN1
Simões, S1
Ansari, J1
Hussain, SA1
Alhasso, A1
Mahmood, R1
Ansari, A1
Glaholm, J1
Hotte, S1
Eigl, B1
Chi, K1
Czaykowski, P1
Wood, L1
Pollak, M1
Berry, S1
Lattouf, JB1
Mukherjee, SD1
Gleave, M1
Flechon, A1
Voog, E1
Davis, NB1
Qi, M1
Bandekar, R1
Vermeulen, JT1
Cornfeld, M1
Hudes, GR1
Shen, YJ1
Bian, XJ1
Xie, HY1
Zhu, Y1
Zhang, HL1
Dai, B1
Zhang, SL1
Yao, XD1
Ye, DW1
Gilligan, T1
Kantoff, PW2
König, E1
Kurbacher, C1
Schwonzen, M1
Breidenbach, M1
Mallmann, P1
Lorusso, V1
Crucitta, E1
Silvestris, N1
Catino, A1
Caporusso, L1
Mazzei, A1
Guida, M1
Latorre, A1
Sambiasi, D1
D'Amico, C1
Schittulli, F1
Calabrese, P1
De Lena, M1
Rago, RP1
Einstein, A1
Lush, R1
Ko, YJ1
Henner, WD1
Bubley, G1
Merica, EA1
Garg, V1
Ette, E1
Harding, MW1
Dalton, WS1
Calais, G1
Ikeda, M1
Okusaka, T1
Ueno, H1
Takezako, Y1
Morizane, C1
Kars, A1
Baltali, E1
Tekuzman, G1
Firat, D1
Alakavuklar, M1
James, ND1
Bloomfield, D1
Luscombe, C1
Collins, R1
Trowman, R1
Norman, G1
Light, K1
Birtle, A1
Fenwick, E1
Palmer, S1
Riemsma, R1
Martinez, V1
Mir, O1
Dômont, J1
Bouscary, D1
Goldwasser, F1
Izumi, K1
Kanno, H1
Umemoto, S1
Hasumi, H1
Osada, Y1
Otai, J1
Mikata, K1
Tsuchiya, F1
Nagashima, Y1
Garrett-Mayer, ES1
Yang, YC1
Thuret, R1
Massard, C1
Gross-Goupil, M1
Escudier, B1
Di Palma, M1
Bossi, A1
de Crevoisier, R1
Chauchereau, A1
Coley, HM1
Yang, X1
Cai, Y1
Zhao, X1
Wang, Z1
Hong, X1
Shen, Z1
Ou, Z1
Li, J1
Hu, X1
Moser, K1
Pohl, A1
Neidhart, JA4
Gochnour, D2
Roach, RW1
Young, D2
Steinberg, JA1
McDonald, DB1
Abu-Zahra, H1
Yoshida, S1
Binder, H1
Holmes, FA4
Yap, HY5
Esparza, L4
Buzdar, AU4
Hortobagyi, GN5
Blumenschein, GR4
Smyth, JF1
Cornbleet, MA1
Stuart-Harris, RC1
Smith, IE1
Coleman, RE1
Rubens, RD1
McDonald, M1
Mouridsen, HT1
Rainer, H1
van Oosterom, AT1
DeSimone, PA1
Gams, R1
Bartolucci, A1
Levin, M1
Pandya, KJ1
Khandekar, JD1
Horton, J1
Glick, JH1
Bennett, JM1
Muggia, FM1
Falkson, G1
Bodey, GP4
Knight, WA1
Von Hoff, DD1
Tranum, BL1
Fabian, C1
Jones, SE2
Bedikian, AY2
Stroehlein, J2
Korinek, J2
Karlin, D2
Valdivieso, M4
Schell, FC2
Blumenschein, G1
Bodey, G1
Frasci, G1
Comella, G1
Comella, P1
Salzano, F1
Cremone, L1
Della Volpe, N1
Imbriani, A1
Persico, G1
Leonardi, V1
Meli, M1
Palmeri, S1
Russo, A1
Rini, GB1
Peralta, S1
Rausa, L1
Ferrero, JM1
Pivot, X1
Namer, M1
Wendling, JL1
Frenay, M1
François, E1
Hoch, M1
Teissier, E1
Hainsworth, JD3
Patrone, F1
Ballestrero, A1
Ferrando, F1
Brema, F1
Moraglio, L1
Valbonesi, M1
Basta, P1
Ghio, R1
Gobbi, M1
Sessarego, M1
Vogel, CL2
Budd, GT1
Herzog, P1
Bukowski, RM1
Neijt, JP1
Lacave, AJ1
Splinter, TA1
Taal, BG1
Veenhof, CH1
Sahmoud, T1
Lips, CJ1
Repetto, L2
Miglietta, L2
Gardin, G2
Lanfranco, C1
Naso, C1
Merlini, L3
Giudici, S1
Venturino, A1
Campora, E1
Testore, F1
Williams, SF1
Myers, SE1
Huffman, S1
Mick, R1
Bitran, JD1
Mundt, AJ1
Sibley, GS1
Williams, S1
Rubin, SJ1
Heimann, R1
Halpern, H1
Weichselbaum, RR1
Mammoliti, S2
Caroti, C2
Gallo, L2
Perrone, F1
De Placido, S1
Carlomagno, C1
Gravina, A1
De Laurentiis, M1
Del Mastro, L1
Gridelli, C1
Pagliarulo, C1
Bianco, AR1
Fields, KK2
Elfenbein, GJ2
Perkins, JB2
Hiemenz, JW1
Janssen, WE1
Zorsky, PE1
Ballester, OF1
Kronish, LE1
Foody, MC1
Louvet, C1
de Gramont, A1
Demuynck, B1
Beerblock, K1
Varette, C1
Soubrane, D1
Marpeau, L1
Pigné, A1
Guillot, T1
Krulik, M1
Gomez, EG1
Brufman, G1
Haim, N1
Ben-Baruch, N1
Sulkes, A1
Lemmens, J1
Berteloot, P1
Thomas, J1
Wildiers, J1
Paridaens, R1
Moscinski, LC1
Long, GD2
Negrin, RS2
Hoyle, CF1
Kusnierz-Glaz, CR1
Schriber, JR1
Blume, KG2
Chao, NJ2
Subar, M1
Muhonen, T1
Jantunen, I1
Pertovaara, H1
Voutilainen, L1
Maiche, A1
Blomqvist, C1
Pyrhönen, S1
Kellokumpu-Lehtinen, P1
Colozza, M1
Gori, S1
Mosconi, AM1
Anastasi, P1
Basurto, C1
Ludovini, V1
De Angelis, V1
Giansanti, M1
Tonato, M1
Azim, HA1
Fippin, LJ1
Ernest, ML1
Carroll, PR1
Gisselbrecht, C4
Extra, JM1
Lotz, JP2
Devaux, Y1
Janvier, M2
Peny, AM1
Guillevin, L1
Bremond, D1
Delain, M1
Herbrecht, R1
Lepage, E1
Maraninchi, D1
Gladieff, L1
Houyau, P1
Mihura, J1
Martinez, M1
Caunes, N1
Chevreau, C1
Bugat, R1
Roché, H2
Cook, AM1
Chambers, EJ1
Rees, GJ1
Panagos, GE1
Ingle, JN1
Kardinal, CG1
Suman, VJ1
Veeder, MH1
Schaefer, PL1
Kirschling, RJ1
Mailliard, JA1
Greco, FA2
Bascioni, R1
Giorgi, F1
Silva, RR1
Acito, L2
Giustini, L2
De Signoribus, G1
Giuliodori, L1
Testa, E1
Gregory, RK1
Powles, TJ1
Chang, JC1
Ashley, S1
Martín, M1
Casado, A1
Llorente, L1
López Martín, JA1
Rodríguez Lescure, A1
Nieto, Y1
Ayala, F1
Pérez Calvo, J1
Alonso, JL1
Pérez López, C1
Villegas, A1
Díaz-Rubio, E1
Pusztai, L1
Fraschini, G1
Kouroussis, C1
Androulakis, N1
Kakolyris, S2
Souglakos, J1
Kotsakis, T1
Mavroudis, D1
Katsogridakis, K1
Vardakis, N1
Hatzidaki, D1
Samonis, G2
Vlachonikolis, J1
Georgoulias, V2
Curé, H1
Morvan, F1
Legros, M1
Asselain, B1
Guillemot, M1
Mohr, M1
Hilgenfeld, E1
Fietz, T1
Hoppe, B1
Koenigsmann, M1
Hoffmann, M1
Knauf, WU1
Cassens, U1
Sibrowski, W1
Kienast, J1
Thiel, E1
Berdel, WE1
Koukourakis, M1
Vlachonicolis, J1
Kalbakis, K1
Agelaki, S1
Chalkiadakis, G1
Sanidas, E1
Tsiftsis, D1
Costanzo, FD1
Sdrobolini, A1
Manzione, L1
Bilancia, D1
Gasperoni, S1
Valenti, L1
Fioriti, L1
Angiona, S1
Cristofanilli, M1
Valero, V1
Conaway, M1
Picus, J1
Kirshner, J1
Hars, V1
Trump, D1
Winer, EP1
Vogelzang, NJ1
Hu, WW1
Stockerl-Goldstein, KE1
Johnston, LJ1
Smith, MR1
Wang, J1
Halford, S1
Rigg, A1
Roylance, R1
Lynch, M1
Waxman, J1
Culine, S2
Droz, JP1
Thurnher, D1
Kornfehl, J1
Burian, M1
Gedlicka, C1
Selzer, E1
Quint, C1
Neuchrist, C1
Kornek, GV1
Harvey, J1
Cantrell, J1
Campbell, M1
Cartmell, A1
Urba, W1
Modiano, M1
Schuster, M1
Rubin, A1
Newcomb, T1
Ghalie, R1
Gazet, JC1
Ford, HT1
Gray, R1
McConkey, C1
Sutcliffe, R1
Quilliam, J1
Makinde, V1
Lowndes, S1
Coombes, RC1
Tan, SM1
Cheung, KL1
Willsher, PC1
Blamey, RW1
Chan, SY1
Robertson, JF1
Colomer, R1
Esteban, E1
Barceló, R1
Benavides, M1
Puertas, J1
Arcediano, A1
Tornamira, MV1
Valentín, V1
Muñoz, A1
Cortés-Funes, H1
Hornedo, J1
Gleave, ME1
Klasa, R1
Murray, N1
Bryce, C1
Lopes de Menezes, DE1
D'Aloisio, S1
Tolcher, AW1
Khalaf, A1
Pfister, C1
Hellot, MF1
Dunet, F1
Moussu, J1
Grise, P1
Degardin, M1
Hecquet, B1
Bonneterre, J1
Adenis, A1
Pion, JM1
Demaille, A1
Gupta, P1
Tandon, R1
Hidalgo, OF1
Gonzalez, FG1
Vieitez, JM1
Rebollo, J1
Tangco, E1
Herranz, P1
Pfeiffer, P1
Cold, S1
Rose, C1
Hu, OY1
Chang, SP1
Law, CK1
Jian, JM1
Chen, KY1
Schaudig, K1
Thomssen, C1
Jänicke, F1
Graeff, H1
Barni, S1
Lissoni, P1
Paolorossi, F1
Rescaldani, R1
Crispino, S1
Archili, C1
Cattaneo, G1
Tancini, G1
Borovik, R1
Robinson, E1
Mennel, RG1
Brooks, B1
Westrick, MA1
Allison, MA1
Paulson, RS1
Tilmann, K1
Rea, B1
Andrews, MB1
Johnson, DH1
Queirolo, P1
Guido, T1
Pronzato, P1
Rosso, R1
Wallerstein, R1
Spitzer, G1
Dunphy, F1
Huan, S1
Hortobagyi, G1
Yau, J1
Buzdar, A1
Holmes, F1
Theriault, R1
Ewer, M1
Thürlimann, B1
Senn, HJ1
Jungi, WF1
Burghouts, JT1
Bishop, JF1
Raghavan, D1
Woods, R1
Coates, A1
Burns, I1
Jeal, PN1
Hillcoat, BL1
Tattersall, MN1
Henderson, IC1
Allegra, JC1
Woodcock, T1
Wolff, S1
Bryan, S1
Cartwright, K1
Dukart, G1
Henry, D1
Runge, HM1
Meerpohl, HG1
Pfleiderer, A1
Hausmaninger, H3
Lehnert, M2
Steger, G1
Sevelda, P1
Michlmayr, G1
Hehenwarter, W1
Fridrik, M1
Samonigg, H1
Schiller, L1
Manfreda, D1
Schlumberger, M1
Parmentier, C1
Belpomme, D2
Cour, V2
Le Rol, A2
Mignot, L1
Marty, M2
Godeffroy, W1
Maral, J2
Shpall, EJ1
Jones, RB1
Holland, JF1
Bhardwaj, S1
Paciucci, PA1
Wilfinger, CL1
Strashun, A1
Büyükünal, E1
Derman, U1
Serdengecti, S1
Berkarda, B1
Roach, R1
Hoth, D1
Gams, RA1
Nelson, O1
Birch, R1
Hug, V1
Heritier, F1
Michaud, G1
George, C1
Bezwoda, WR1
Hesdorffer, CS1
Dansey, RD1
Nathanson, L1
Williams, ME1
Ogawa, M1
Kubo, K1
Tominaga, T1
Nomura, Y1
Ota, K1
Yoshida, M1
Taguchi, T1
Hoshino, A1
Wilson, KS1
Paterson, AH1
Muss, HB1
Bundy, BN1
DiSaia, PJ1
Ehrlich, CE1

Clinical Trials (6)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Randomized, Open Label Multi-Center Study of XRP6258 at 25 mg/m^2 in Combination With Prednisone Every 3 Weeks Compared to Mitoxantrone in Combination With Prednisone For The Treatment of Hormone Refractory Metastatic Prostate Cancer Previously Treated [NCT00417079]Phase 3755 participants (Actual)Interventional2007-01-31Completed
Phase I/II Trial of Epothilone Analog BMS-247550 (Ixabepilone), Mitoxantrone, and Prednisone in Hormone Refractory Prostate Cancer (HRPC) Patients Previously Treated With Chemotherapy[NCT00331344]Phase 1/Phase 2100 participants (Actual)Interventional2006-04-30Completed
A Phase II Trial of Cabazitaxel Chemotherapy in Relapsed Locally Advanced &/or Metastatic Carcinoma of the Penis[NCT03114254]Phase 217 participants (Actual)Interventional2014-12-05Completed
A Randomized Phase 3 Study Comparing Cabazitaxel/Prednisone in Combination With Custirsen (OGX-011) to Cabazitaxel/Prednisone for Second-Line Chemotherapy in Men With Metastatic Castrate Resistant Prostate Cancer (AFFINITY)[NCT01578655]Phase 3630 participants (Actual)Interventional2012-08-31Completed
Title: A Pilot Study Evaluating the Safety and Feasibility of Custirsen (OGX-011) in Combination With Second Line Chemotherapy in Patients With Hormone Refractory Prostate Cancer[NCT00327340]Phase 270 participants (Actual)Interventional2006-07-31Completed
A Phase II Study of Oral Calcitriol in Combination With Ketoconazole in Castration Resistant Prostate Cancer, Progressing Despite Primary ADT and Abiraterone[NCT03261336]Phase 21 participants (Actual)Interventional2017-01-06Terminated (stopped due to can not meet enrollment)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Overall Survival

"Overall survival was defined as the time interval from the date of randomization to the date of death due to any cause.~In the absence of confirmation of death, the survival time was censored at the last date patient was known to be alive or at the cut-off date, whichever had come first." (NCT00417079)
Timeframe: From the date of randomization up to 104 weeks (study cut-off)

InterventionMonths (Median)
Mitoxantrone + Prednisone12.7
Cabazitaxel + Prednisone15.1

Overall Tumor Response

"Tumor Overall Response Rate (ORR) (only in patients with measurable disease):~Objective responses (Complete Response and Partial Response) for measurable disease as assessed by investigators according to RECIST criteria.~Complete Response (CR) is defined as: Disappearance of all target lesions. Partial Response (PR) is defined as: At least a 30% decrease in the sum of longest diameter (LD) of target lesions taking as reference baseline sum LD.~Confirmation of objective responses will be performed by repeat tumor imaging (CT scans, MRI, bone scans) after the first documentation of response." (NCT00417079)
Timeframe: From the date of randomization up to 104 weeks (study cut-off)

Interventionpercentage of participants (Number)
Mitoxantrone + Prednisone4.4
Cabazitaxel + Prednisone14.4

Pain Response

Pain Response was defined as a two-point or greater reduction from baseline median Present Pain Intensity (PPI) score without an increased Analgesic Score (AS) or a decrease of ≥50% in the AS without an increase in the PPI score, maintained for at least 3 weeks. (NCT00417079)
Timeframe: from baseline up to 104 weeks (study cut-off)

InterventionPercentage of participants (Number)
Mitoxantrone + Prednisone7.7
Cabazitaxel + Prednisone9.2

PSA (Prostate-Specific Antigen) Response

PSA response was defined as a ≥ 50% reduction in serum PSA, determined only for patients with a serum PSA ≥ 20ng/mL at baseline, confirmed by a repeat PSA ≥ 3 weeks later. (NCT00417079)
Timeframe: from baseline up to 104 weeks (study cut-off)

InterventionPercentage of participants (Number)
Mitoxantrone + Prednisone17.8
Cabazitaxel + Prednisone39.2

Time to Pain Progression

"Pain Progression is defined as an increase of ≥1 point in the median Personal Pain Intensity (PPI) from its nadir noted on 2 consecutive 3-week-apart visits or ≥25 % increase in the mean analgesic score compared with the baseline score & noted on 2 consecutive 3-week-apart visits or requirement for local palliative radiotherapy.~Evaluation of the PPI & analgesic scores are based on the short-form McGill Pain Questionnaire which consists of 15 descriptors (11 sensory; 4 affective) which are rated on an intensity scale as 0=none (best) 1=mild 2=moderate 3=severe (worst) (TOTAL: 0=best 45=worst)" (NCT00417079)
Timeframe: from baseline up to 104 weeks (study cut-off)

InterventionMonths (Median)
Mitoxantrone + PrednisoneNA
Cabazitaxel + Prednisone11.1

Time to Progression Free Survival (PFS)

Progression free survival was defined as a composite endpoint evaluated from the date of randomization to the date of tumor progression, PSA progression, pain progression, or death due to any cause, whichever occurred first (NCT00417079)
Timeframe: From the date of randomization up to 104 weeks (study cut-off)

InterventionMonths (Median)
Mitoxantrone + Prednisone1.4
Cabazitaxel + Prednisone2.8

Time to Prostatic Specific Antigen (PSA) Progression

"In PSA non-responders, progression will be defined as a 25% increase over nadir and increase in the absolute value PSA level by at least 5 ng/ml and confirmed by a second value at least 4 weeks later.~In PSA responders and in patients not evaluable for PSA response at baseline, progression will be defined as a ≥50% increase over nadir, provided that the increase is a minimum of 5 ng/ml and confirmed by a second value at least 1 week later." (NCT00417079)
Timeframe: at screening, day 1 of every treatment cycle, up to 104 weeks (study cut-off)

InterventionMonths (Median)
Mitoxantrone + Prednisone3.1
Cabazitaxel + Prednisone6.4

Time to Tumor Progression

Time to tumor progression is defined as the number of months from randomization until evidence of progressive disease (RECIST) (NCT00417079)
Timeframe: From the date of randomization up to 104 weeks (study cut-off)

InterventionMonths (Median)
Mitoxantrone + Prednisone5.4
Cabazitaxel + Prednisone8.8

Dose Limiting Toxicities for Each Dose Level of Ixabepilone, Mitoxantrone Hydrochloride, and Prednisone in Patients With Hormone-refractory Metastatic Prostate Cancer That Progressed During or After Taxane-based Chemotherapy (Phase I).

Cohorts of 3 patients will be enrolled at each dose level; if 1 dose limiting toxicity (DLT) is observed then the cohort will be expanded to 6 patients. If a second DLT is observed, the previous dose level will be considered the maximum tolerated dose (MTD). If all observed DLT are due to neuropathy (specific to ixabepilone), then we would consider the previous dose level of Ixabepilone the MTD for that drug, and escalate mitoxantrone hydrochloride as described above to a maximum dose of 12 mg/m^2. Toxicities will be tabulated by grade for each dose cohort and overall for all patients accrued to the phase I study. (NCT00331344)
Timeframe: Course 1 (first 21 days)

InterventionParticipants (Count of Participants)
Phase I Group I0
Phase Group II0
Phase I Group III0
Phase I Group IV1
Phase I Group V2
Phase I Group VI2
Phase I Group Va0
Phase I Group VIa1

Proportion Responding to Treatment With of the Combination of Ixabepilone and Mitoxantrone Hydrochloride With Prednisone in Hormone Refractory Prostate Cancer Patients Who Have Had Prior Taxane Chemotherapy Based Upon a PSA Decline of > 50% (Phase II)

"Descriptive statistics will be calculated to characterize the disease and treatment factors including the proportion responding with a 95% confidence interval. If accrual is completed and more than 15 of 58 patients show > 50% Prostate Specific Antigen (PSA) declines after 3 courses, then the null hypothesis of a 20% response proportion will be rejected. PSA declines for individual patients will be plotted in the form of a waterfall diagram of maximal PSA declines.~58 patients were enrolled for phase II, two were ineligible so 56 patients were analyzed." (NCT00331344)
Timeframe: Every 3 courses until cancer progression/excessive toxicity or death

InterventionParticipants (Count of Participants)
Treatment (Combination Chemotherapy)25

Safety of the Combination of Ixabepilone, Mitoxantrone Hydrochloride, and Prednisone in Patients With Hormone-refractory Metastatic Prostate Cancer That Progressed During or After Taxane-based Chemotherapy (Phase I)

This study will utilize the Common Terminology Criteria for Adverse Events (CTCAE) v3.0 for adverse event monitoring and reporting. The cumulative grade 3 or higher adverse events for all dose levels are noted below and in the table of adverse events. (NCT00331344)
Timeframe: Every 21 days until cancer progression/excessive toxicity or death

InterventionAdverse Events (above threshold) (Number)
Phase I Treatment (Groups I-VIa)62

Time to Progression (Phase II)

Measured from the start of protocol therapy until RECIST (Response Evaluation Criteria In Solid Tumors Criteria) v1.0 progression. Progression is defined as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. (NCT00331344)
Timeframe: Every 3 months until cancer progression/excessive toxicity or death

Interventionmonths (Median)
Treatment (Combination Chemotherapy)4.4

Feasibility of Treatment With Custirsen (OGX-011) in Combination With Second-line Chemotherapy Based on Prostate Specific Antigen (PSA) Response

PSA or prostate specific antigen is a marker for prostate cancer. A PSA response was defined as a decrease in PSA values of ≥ 50% relative to baseline on two or more consecutive measurements that were 4-6 weeks apart. (NCT00327340)
Timeframe: PSA was evaluated at screening, on Day 1 of each cycle, at the end of treatment visit and during off-treatment follow up (up to 27 months)

Interventionpercentage of participants (Number)
OGX-011 / Mitoxantrone/Prednisone17
OGX-011 / Docetaxel/Prednisone31

Feasibility of Treatment With OGX-011 in Combination With Either Docetaxel/Prednisone or Mitoxantrone/Prednisone as Second Line Chemotherapy Based on Time to Pain Progression

Time to pain progression was defined as the time (months) from the first dose of OGX-011 to the first documentation of pain or analgesic progression or initiation of palliative radiation therapy. Pain response was defined as either a decrease of at least two points on the 11-point Worst Pain Scale, without an increase in analgesic level, maintained for at least two consecutive measurements approximately three weeks apart -or- a decrease in analgesic level, without an increase in pain score, maintained for at least two consecutive measurements approximately three weeks apart. (NCT00327340)
Timeframe: Enrollment until pain progression (up to 21 months)

Interventionmonths (Number)
OGX-011 + Mitoxantrone + Prednisone5.2
OGX-011 + Docetaxel + Prednisone7.2

Relationship Between Changes in Serum Clusterin Levels and Change in Serum PSA Levels When OGX-011 in Combination With Either Docetaxel/Prednisone or Mitoxantrone/Prednisone is Administered as Second Line Chemotherapy.

Serum clusterin samples were collected prior to receiving OGX-011 loading dose 1, prior to study treatment on Day 1 of each cycle, and at the end of treatment. PSA was evaluated at screening, on Day 1 of each cycle, at the end of treatment visit, and during off-treatment follow-up. PSA response was defined in the protocol as a decrease in PSA of ≥ 50% relative to baseline on two or more consecutive measurements 4-6 weeks apart. (NCT00327340)
Timeframe: Enrollment until disease progression (up to 13 months)

,
Interventionpercentage of participants (Number)
Minimum clusterin level < or = to 45 mcg/mLMinimum clusterin level > 45 mcg/mL
OGX-011 + Docetaxel + Prednisone247
OGX-011 + Mitoxantrone + Prednisone224

Safety and Tolerability of Custirsen (OGX-011) in Combination With Either Docetaxel/Prednisone or Mitoxantrone/Prednisone as Second-line Chemotherapy.

"Safety and tolerability were based on Adverse Events (AE) and Serious Adverse Events (SAE) graded using National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE).~The CTCAE has 5 grades with unique clinical descriptions of severity for each AE based on this general guideline: Grade 1=Mild AE; Grade 2=Moderate AE; Grade 3=Severe AE; Grade 4=Life-threatening or disabling AE; and Grade 5=Death related to AE." (NCT00327340)
Timeframe: Subjects were followed for safety from enrollment for up to 8 months (9 three-week cycles plus 30 days after end of treatment)

,
Interventionpercentage of participants (Number)
Percent of Subjects with Serious Adverse EventsPercent of Subjects with Grade 5 Adverse EventsPercent of Subjects with Grade 4 Adverse EventsPercent of Subjects with Grade 3 Adverse EventsPercent of Subjects with Grade 2 Adverse EventsPercent of Subjects with Grade 1 Adverse EventsPercent of Subjects who Discontinued Study Drug
OGX-011 + Docetaxel + Prednisone26415529810017
OGX-011 + Mitoxantrone + Prednisone261326708310022

Toxicity and Tolerability of Experimental Arm

Descriptive analysis of observed toxicity and patient reports of tolerating experimental treatment (NCT03261336)
Timeframe: 2 years

InterventionParticipants (Count of Participants)
Calcitriol, Ketoconazole, Hydrocortisone1

Reviews

17 reviews available for mitoxantrone and Neoplasm Metastasis

ArticleYear
Cost-effectiveness analyses and cost analyses in castration-resistant prostate cancer: A systematic review.
    PloS one, 2018, Volume: 13, Issue:12

    Topics: Aged; Antineoplastic Agents; Bias; Cost-Benefit Analysis; Humans; Male; Middle Aged; Mitoxantrone; N

2018
Overall Survival of Black and White Men With Metastatic Castration-Resistant Prostate Cancer Treated With Docetaxel.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019, 02-10, Volume: 37, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Black People; Clinical Trials, Phase III as Topic; D

2019
Metastatic castration-resistant prostate cancer. Part 1: the challenges of the disease and its treatment.
    European journal of oncology nursing : the official journal of European Oncology Nursing Society, 2013, Volume: 17 Suppl 1

    Topics: Alpha Particles; Androstenes; Androstenols; Antineoplastic Agents; Benzamides; Cancer Vaccines; Chlo

2013
Systemic therapy after first-line docetaxel in metastatic castration-resistant prostate cancer.
    Current opinion in supportive and palliative care, 2008, Volume: 2, Issue:3

    Topics: Antineoplastic Agents; Clinical Trials as Topic; Disease-Free Survival; Docetaxel; Epothilones; Huma

2008
Role of second-line systemic treatment post-docetaxel in metastatic castrate resistant prostate cancer- current strategies and future directions.
    Anti-cancer agents in medicinal chemistry, 2011, Volume: 11, Issue:3

    Topics: Androstenes; Androstenols; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cl

2011
Chemotherapy for prostate cancer.
    Urology, 2002, Volume: 60, Issue:3 Suppl 1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Chemotherapy, Adjuvant; Clin

2002
[Radiation and concomitant chemotherapy after surgery for breast cancer].
    Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique, 2004, Volume: 8, Issue:1

    Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; An

2004
The changing pattern of management for hormone-refractory, metastatic prostate cancer.
    Prostate cancer and prostatic diseases, 2006, Volume: 9, Issue:3

    Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocol

2006
A systematic review of the effectiveness of docetaxel and mitoxantrone for the treatment of metastatic hormone-refractory prostate cancer.
    British journal of cancer, 2006, Aug-21, Volume: 95, Issue:4

    Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Res

2006
Mechanisms and strategies to overcome chemotherapy resistance in metastatic breast cancer.
    Cancer treatment reviews, 2008, Volume: 34, Issue:4

    Topics: Breast Neoplasms; Carrier Proteins; DNA Repair; Drug Delivery Systems; Drug Resistance, Multiple; Dr

2008
[Recent developments in chemotherapy of malignant diseases].
    Wiener klinische Wochenschrift, 1982, Dec-10, Volume: 94, Issue:23

    Topics: Anthraquinones; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy

1982
Combination chemotherapy with vinorelbine (Navelbine) and mitoxantrone for metastatic breast cancer: a review.
    Seminars in oncology, 1995, Volume: 22, Issue:2 Suppl 5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Female;

1995
High dose versus standard dose chemotherapy for the treatment of breast cancer. A review of current concepts.
    Annals of the New York Academy of Sciences, 1995, Dec-29, Volume: 770

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Busulfan; Carboplatin; Cycl

1995
Chemotherapy in advanced androgen-independent prostate cancer 1990-1999: a decade of progress?
    Annals of oncology : official journal of the European Society for Medical Oncology, 2000, Volume: 11, Issue:12

    Topics: Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemothe

2000
[A study of VMMC protocol (vindesine, mitoxantrone, mitomycin C) as a salvage chemotherapy in advanced breast cancers].
    Bulletin du cancer, 1992, Volume: 79, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dose-Response Relatio

1992
Cytotoxic treatment of metastatic breast cancer. Which drugs and drug combinations to use?
    Acta oncologica (Stockholm, Sweden), 1992, Volume: 31, Issue:2

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin;

1992
Pharmacokinetic and pharmacodynamic studies with mitoxantrone in the treatment of patients with nasopharyngeal carcinoma.
    Cancer, 1992, Feb-15, Volume: 69, Issue:4

    Topics: Adult; Chromatography, High Pressure Liquid; Female; Humans; Male; Metabolic Clearance Rate; Middle

1992

Trials

80 trials available for mitoxantrone and Neoplasm Metastasis

ArticleYear
Randomised phase II study of second-line olaratumab with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer.
    European journal of cancer (Oxford, England : 1990), 2019, Volume: 107

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco

2019
Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2013, Volume: 24, Issue:9

    Topics: Aged; Aged, 80 and over; Analgesics; Antineoplastic Agents; Docetaxel; Humans; Male; Middle Aged; Mi

2013
Ixabepilone, mitoxantrone, and prednisone for metastatic castration-resistant prostate cancer after docetaxel-based therapy: a phase 2 study of the Department Of Defense Prostate Cancer Clinical Trials Consortium.
    Cancer, 2011, Jun-01, Volume: 117, Issue:11

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Epothilones; Hum

2011
Prostate-specific antigen changes as surrogate for overall survival in men with metastatic castration-resistant prostate cancer treated with second-line chemotherapy.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Nov-01, Volume: 31, Issue:31

    Topics: Aged; Androgen Antagonists; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Drug Resistance,

2013
Clinical benefits of non-taxane chemotherapies in unselected patients with symptomatic metastatic castration-resistant prostate cancer after docetaxel: the GETUG-P02 study.
    BJU international, 2015, Volume: 115, Issue:1

    Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Eto

2015
Severe neutropenia during cabazitaxel treatment is associated with survival benefit in men with metastatic castration-resistant prostate cancer (mCRPC): A post-hoc analysis of the TROPIC phase III trial.
    European journal of cancer (Oxford, England : 1990), 2016, Volume: 56

    Topics: Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Granulocyte Colony

2016
The Canadian Uro-Oncology Group multicentre phase II study of docetaxel administered every 3 weeks with prednisone in men with metastatic hormone-refractory prostate cancer progressing after mitoxantrone/prednisone.
    BJU international, 2008, Aug-05, Volume: 102, Issue:5

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Docetaxel; Humans; Male;

2008
The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survival.
    European journal of cancer (Oxford, England : 1990), 2010, Volume: 46, Issue:3

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Mitoxantrone; Neoplas

2010
A randomized phase II trial of mitoxantrone, estramustine and vinorelbine or bcl-2 modulation with 13-cis retinoic acid, interferon and paclitaxel in patients with metastatic castrate-resistant prostate cancer: ECOG 3899.
    Journal of translational medicine, 2010, Feb-24, Volume: 8

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Estr

2010
TROPIC: Phase III trial of cabazitaxel for the treatment of metastatic castration-resistant prostate cancer.
    Future oncology (London, England), 2011, Volume: 7, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Castration; Cell Line, Tumor; Disease-Free Survival;

2011
Randomized phase II trial of Custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG trial P-06c.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, Sep-01, Volume: 17, Issue:17

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clusterin; Docetaxel; Drug

2011
Randomized phase II trial of Custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG trial P-06c.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, Sep-01, Volume: 17, Issue:17

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clusterin; Docetaxel; Drug

2011
Randomized phase II trial of Custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG trial P-06c.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, Sep-01, Volume: 17, Issue:17

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clusterin; Docetaxel; Drug

2011
Randomized phase II trial of Custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG trial P-06c.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, Sep-01, Volume: 17, Issue:17

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clusterin; Docetaxel; Drug

2011
Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer.
    European journal of cancer (Oxford, England : 1990), 2012, Volume: 48, Issue:1

    Topics: Aged; Aged, 80 and over; Algorithms; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Pr

2012
[Docetaxel plus prednisone versus mitoxantrone plus prednisone as first-line chemotherapy for metastatic hormone-refractory prostate cancer: long-term effects and safety].
    Zhonghua wai ke za zhi [Chinese journal of surgery], 2012, Volume: 50, Issue:6

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Middle Aged; Mitoxant

2012
A phase II study of dose-dense docetaxel and mitoxantrone in the treatment of patients with high-risk metastatic breast cancer.
    Anti-cancer drugs, 2002, Volume: 13, Issue:8

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel

2002
Phase I/II study of gemcitabine plus mitoxantrone as salvage chemotherapy in metastatic breast cancer.
    British journal of cancer, 2003, Feb-24, Volume: 88, Issue:4

    Topics: Adult; Aged; Bone Neoplasms; Breast Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug

2003
Safety and efficacy of the MDR inhibitor Incel (biricodar, VX-710) in combination with mitoxantrone and prednisone in hormone-refractory prostate cancer.
    Cancer chemotherapy and pharmacology, 2003, Volume: 51, Issue:4

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under

2003
[Radiation and concomitant chemotherapy after surgery for breast cancer].
    Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique, 2004, Volume: 8, Issue:1

    Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; An

2004
A phase II trial of continuous infusion of 5-fluorouracil, mitoxantrone, and cisplatin for metastatic hepatocellular carcinoma.
    Cancer, 2005, Feb-15, Volume: 103, Issue:4

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepat

2005
A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2007, Nov-01, Volume: 13, Issue:21

    Topics: Algorithms; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Female; Humans; Kinetics; Mal

2007
Biweekly docetaxel-containing chemotherapy may be the optimal schedule.
    Anti-cancer drugs, 2008, Volume: 19, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Drug Admin

2008
A comparative trial of mitoxantrone and doxorubicin in patients with minimally pretreated breast cancer.
    Seminars in oncology, 1984, Volume: 11, Issue:3 Suppl 1

    Topics: Adult; Aged; Anthraquinones; Breast Neoplasms; Clinical Trials as Topic; Doxorubicin; Female; Heart;

1984
Mitoxantrone and cyclophosphamide in advanced breast cancer: a pilot study.
    Seminars in oncology, 1984, Volume: 11, Issue:3 Suppl 1

    Topics: Adult; Aged; Anthraquinones; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols;

1984
Mitoxantrone, cyclophosphamide, and 5-fluorouracil in the treatment of hormonally unresponsive metastatic breast cancer.
    Seminars in oncology, 1984, Volume: 11, Issue:3 Suppl 1

    Topics: Adult; Aged; Anthraquinones; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols;

1984
Mitoxantrone plus vinorelbine with granulocyte-colony stimulating factor (G-CSF) support in advanced breast cancer patients. A dose and schedule finding study.
    Breast cancer research and treatment, 1995, Volume: 35, Issue:2

    Topics: Adenocarcinoma; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neo

1995
A phase II trial of mitoxantrone plus cyclophosphamide and 5-fluorouracil in modulation with levo-folinate for advanced breast cancer patients.
    Journal of chemotherapy (Florence, Italy), 1995, Volume: 7, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dos

1995
[Combination of mitoxantrone-vinorelbine as first-line chemotherapy for metastatic breast carcinoma].
    Bulletin du cancer, 1995, Volume: 82, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dose-Response Relatio

1995
The use of mitoxantrone, 5-fluorouracil and high-dose leucovorin in the treatment of advanced breast cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1993, Volume: 4 Suppl 2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Fluorouracil;

1993
Four-step high-dose sequential chemotherapy with double hematopoietic progenitor-cell rescue for metastatic breast cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1995, Volume: 13, Issue:4

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Combined Modal

1995
Phase I/II trial of dipyridamole, 5-fluorouracil, leukovorin, and mitoxantrone in metastatic breast cancer.
    Investigational new drugs, 1994, Volume: 12, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Breast Neoplasms;

1994
Mitoxantrone in metastatic apudomas: a phase II study of the EORTC Gastro-Intestinal Cancer Cooperative Group.
    British journal of cancer, 1995, Volume: 71, Issue:1

    Topics: Adenoma, Islet Cell; Adult; Aged; Alkaline Phosphatase; Apudoma; Carcinoid Tumor; Carcinoma, Medulla

1995
Phase II study of weekly mitoxantrone, 5-fluorouracil, and leucovorin in metastatic breast cancer.
    Breast cancer research and treatment, 1994, Volume: 30, Issue:2

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedul

1994
Patterns of failure of complete responders following high-dose chemotherapy and autologous bone marrow transplantation for metastatic breast cancer: implications for the use of adjuvant radiation therapy.
    International journal of radiation oncology, biology, physics, 1994, Aug-30, Volume: 30, Issue:1

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Breast Neoplasms

1994
Mitoxantrone, 5-fluorouracil and levo-leucovorin as salvage treatment in advanced breast cancer patients.
    European journal of cancer (Oxford, England : 1990), 1994, Volume: 30A, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Fluorouracil;

1994
Mitomycin C and mitoxantrone in anthracycline-pretreated advanced breast cancer patients. A phase II study.
    American journal of clinical oncology, 1994, Volume: 17, Issue:3

    Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neo

1994
Two novel high-dose treatment regimens for metastatic breast cancer--ifosfamide, carboplatin, plus etoposide and mitoxantrone plus thiotepa: outcomes and toxicities.
    Seminars in oncology, 1993, Volume: 20, Issue:5 Suppl 6

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Breast Neoplasms

1993
Folinic acid, 5-fluorouracil bolus and infusion and mitoxantrone with or without cyclophosphamide in metastatic breast cancer.
    European journal of cancer (Oxford, England : 1990), 1993, Volume: 29A, Issue:13

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Cyclo

1993
A phase I clinical trial of a combination of mitoxantrone, 5-fluorouracil, and high-dose leucovorin given on a day 1 and day 8 schedule to patients with metastatic breast cancer.
    American journal of clinical oncology, 1994, Volume: 17, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration S

1994
Second-line chemotherapy with mitoxantrone as a single agent in metastatic breast cancer.
    Journal of chemotherapy (Florence, Italy), 1993, Volume: 5, Issue:1

    Topics: Adult; Aged; Breast Neoplasms; Female; Humans; Infusions, Intravenous; Middle Aged; Mitoxantrone; Ne

1993
Mitoxantrone, 5-fluorouracil and leucovorin in metastatic breast cancer.
    European journal of cancer (Oxford, England : 1990), 1995, Volume: 31A, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Fe

1995
Prophylactic filgrastim (G-CSF) during mitomycin-C, mitoxantrone, and methotrexate (MMM) treatment for metastatic breast cancer. A randomized study.
    American journal of clinical oncology, 1996, Volume: 19, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Filgrastim; G

1996
Salvage chemotherapy in metastatic breast cancer: an experience with the combination of mitoxantrone, 5-fluorouracil, and L-leucovorin.
    Breast cancer research and treatment, 1996, Volume: 38, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Fluorouracil;

1996
Phase II study of mitoxantrone, 5-fluorouracil, and levo-leucovorin (MLF) in elderly advanced breast cancer patients.
    Breast cancer research and treatment, 1996, Volume: 37, Issue:1

    Topics: Aged; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Fluoroura

1996
Treatment of metastatic breast cancer by navelbine, mitoxantrone and continuous infusion 5-fluorouracil (FMN regimen): results of a pilot study.
    The Journal of infusional chemotherapy, 1996,Spring, Volume: 6, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration S

1996
A carboplatin-based regimen for the treatment of patients with advanced transitional cell carcinoma of the urothelium.
    Cancer, 1996, Oct-15, Volume: 78, Issue:8

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Tra

1996
Cyclophosphamide/mitoxantrone/melphalan (CMA) regimen prior to autologous bone marrow transplantation (ABMT) in metastatic breast cancer.
    Bone marrow transplantation, 1996, Volume: 18, Issue:5

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Breast Neoplasms

1996
[A phase II study with mitoxantrone-vinorelbine association in the treatment of advanced breast cancer in elderly women].
    Bulletin du cancer, 1996, Volume: 83, Issue:9

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Pro

1996
Comparison of mitozantrone and epirubicin in advanced breast cancer.
    Clinical oncology (Royal College of Radiologists (Great Britain)), 1996, Volume: 8, Issue:6

    Topics: Antineoplastic Agents; Breast Neoplasms; Epirubicin; Heart Diseases; Humans; Middle Aged; Mitoxantro

1996
Treatment of advanced and relapsing breast cancer with a combination of paclitaxel and mitoxantrone. South-Central Hellenic Oncology Group.
    Seminars in oncology, 1997, Volume: 24, Issue:1 Suppl 3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cardiac Output, Low;

1997
Mitoxantrone dose augmentation utilizing filgrastim support in combination with fixed-dose 5-fluorouracil and leucovorin in women with metastatic breast cancer.
    Breast cancer research and treatment, 1997, Volume: 43, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dose-Response Relatio

1997
Paclitaxel with mitoxantrone with or without 5-fluorouracil and high-dose leucovorin in the treatment of metastatic breast cancer.
    Seminars in oncology, 1997, Volume: 24, Issue:5 Suppl 17

    Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedule; Fema

1997
Mitoxantrone, fluorouracil, and L-folinic acid in anthracycline-pretreated metastatic breast cancer patients.
    Breast cancer research and treatment, 1997, Volume: 45, Issue:3

    Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neo

1997
A randomised trial of six versus twelve courses of chemotherapy in metastatic carcinoma of the breast.
    European journal of cancer (Oxford, England : 1990), 1997, Volume: 33, Issue:13

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dis

1997
Phase II study of mitoxantrone by 14-day continuous infusion with granulocyte colony-stimulating factor (GCSF) support in patients with metastatic breast cancer and limited prior therapy.
    Cancer chemotherapy and pharmacology, 1999, Volume: 43, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Dose-Response Relationship,

1999
Dose-escalation study of docetaxel in combination with mitoxantrone as first-line treatment in patients with metastatic breast cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1999, Volume: 17, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Dose-Respo

1999
[Intensive chemotherapy and autograft of hematopoietic stem cells in the treatment of metastatic cancer: results of the national protocol Pegase 04].
    Hematology and cell therapy, 1999, Volume: 41, Issue:2

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy;

1999
Efficacy and safety of simultaneous immunomagnetic CD34+ cell selection and breast cancer cell purging in peripheral blood progenitor cell samples used for hematopoietic rescue after high-dose therapy.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 1999, Volume: 5, Issue:5

    Topics: Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Combi

1999
First-line treatment with mitoxantrone, methotrexate, vincristine, and carboplatine (MIMOC) plus cyclical hormonotherapy with tamoxifen and megestrol acetate in advanced breast cancer.
    American journal of clinical oncology, 1999, Volume: 22, Issue:3

    Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast

1999
Dose intensification of mitoxantrone in combination with paclitaxel in advanced breast cancer: a phase II study.
    Breast cancer research and treatment, 1999, Volume: 54, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression;

1999
Phase I/II trial of high dose mitoxantrone in metastatic breast cancer: the M.D. Anderson Cancer Center experience.
    Breast cancer research and treatment, 1999, Volume: 54, Issue:3

    Topics: Adult; Algorithms; Breast Neoplasms; Dose-Response Relationship, Drug; Female; Humans; Middle Aged;

1999
Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1999, Volume: 17, Issue:8

    Topics: Aged; Anti-Inflammatory Agents; Antineoplastic Agents; Drug Therapy, Combination; Humans; Hydrocorti

1999
A feasibility study of multiple cycle therapy with melphalan, thiotepa, and paclitaxel followed by mitoxantrone, thiotepa, and paclitaxel with autologous hematopoietic cell support for metastatic breast cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 1999, Volume: 5, Issue:11

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Feasibility Studies; Female

1999
Adjuvant mitozantrone chemotherapy in advanced prostate cancer.
    BJU international, 2000, Volume: 86, Issue:6

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chem

2000
Ifosfamide and mitoxantrone in the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck.
    Anti-cancer drugs, 2001, Volume: 12, Issue:3

    Topics: Adult; Aged; Anemia; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Carcinoma,

2001
Mitoxantrone and paclitaxel combination chemotherapy in metastatic breast cancer.
    Cancer investigation, 2001, Volume: 19, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression;

2001
Estrogen-receptor-directed neoadjuvant therapy for breast cancer: results of a randomised trial using formestane and methotrexate, mitozantrone and mitomycin C (MMM) chemotherapy.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2001, Volume: 12, Issue:5

    Topics: Adult; Aged; Androstenedione; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic

2001
Locally advanced primary breast cancer: medium-term results of a randomised trial of multimodal therapy versus initial hormone therapy.
    European journal of cancer (Oxford, England : 1990), 2001, Volume: 37, Issue:18

    Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast

2001
High-dose mitoxantrone and cyclophosphamide without stem cell support in patients with high-risk and advanced breast carcinoma: a Phase II multicentric trial.
    Cancer, 2001, Nov-15, Volume: 92, Issue:10

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Female; G

2001
A phase I dose-finding study of combined treatment with an antisense Bcl-2 oligonucleotide (Genasense) and mitoxantrone in patients with metastatic hormone-refractory prostate cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2001, Volume: 7, Issue:12

    Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Do

2001
[A study of VMMC protocol (vindesine, mitoxantrone, mitomycin C) as a salvage chemotherapy in advanced breast cancers].
    Bulletin du cancer, 1992, Volume: 79, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dose-Response Relatio

1992
Carboplatin (CBDCA), 5-fluorouracil (5-FU) and mitoxantrone (DHAD): an effective and well tolerated regimen for metastatic breast cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1992, Volume: 3, Issue:7

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Drug Eva

1992
[Mitoxantrone monotherapy in metastatic breast cancer--initial results of a prospective randomized study in "low risk" patients].
    Gynakologische Rundschau, 1991, Volume: 31 Suppl 2

    Topics: Breast Neoplasms; Drug Administration Schedule; Female; Humans; Mitoxantrone; Neoplasm Metastasis; P

1991
Phase II study of mitoxantrone, leucovorin, and infusional fluorouracil for treatment of metastatic breast cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1991, Volume: 9, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dr

1991
Mitoxantrone, fluorouracil, and high-dose leucovorin: an effective, well-tolerated regimen for metastatic breast cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1991, Volume: 9, Issue:10

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality The

1991
Randomized clinical trial comparing mitoxantrone with doxorubicin in previously treated patients with metastatic breast cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1989, Volume: 7, Issue:5

    Topics: Adenocarcinoma; Breast Neoplasms; Clinical Trials as Topic; Doxorubicin; Drug Evaluation; Female; He

1989
Vindesine-epirubicin versus vindesine-mitoxantrone in metastatic breast cancer.
    Onkologie, 1989, Volume: 12, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Epirubicin; Female; G

1989
Intensive single-agent mitoxantrone for metastatic breast cancer.
    Journal of the National Cancer Institute, 1988, Apr-06, Volume: 80, Issue:3

    Topics: Breast Neoplasms; Clinical Trials as Topic; Doxorubicin; Female; Humans; Leukopenia; Mitoxantrone; N

1988
Vindesine-mitoxantrone (VM) versus vindesine-4'-epidoxorubicin (VE) in metastatic breast cancer: a prospective randomized trial.
    Onkologie, 1988, Volume: 11, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Doxorubicin; Drug Administration S

1988
A clinical trial of mitoxantrone (novantrone) versus doxorubicin (adriamycin) in combination chemotherapy for metastatic breast cancer.
    Chemioterapia : international journal of the Mediterranean Society of Chemotherapy, 1987, Volume: 6, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Clini

1987
A comparison of mitoxantrone and doxorubicin in breast cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1986, Volume: 4, Issue:5

    Topics: Adult; Aged; Anthraquinones; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Dose

1986
Phase II evaluation of mitoxantrone in advanced renal cell carcinoma: a Southeastern Cancer Study Group Trial.
    Cancer treatment reports, 1986, Volume: 70, Issue:7

    Topics: Adult; Anthraquinones; Antineoplastic Agents; Carcinoma, Renal Cell; Clinical Trials as Topic; Drug

1986

Other Studies

48 other studies available for mitoxantrone and Neoplasm Metastasis

ArticleYear
Synthesis and biological properties of polyamine modified flavonoids as hepatocellular carcinoma inhibitors.
    European journal of medicinal chemistry, 2016, Oct-04, Volume: 121

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis Regulatory Proteins; Aspirin; Car

2016
A Nanoplatform to Amplify Apoptosis-to-Pyroptosis Immunotherapy via Immunomodulation of Myeloid-Derived Suppressor Cells.
    ACS applied materials & interfaces, 2021, Oct-13, Volume: 13, Issue:40

    Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Drug Carriers; Drug Liberation; Female;

2021
In silico screening for ERα down modulators identifies thioridazine as an anti-proliferative agent in primary, 4OH-tamoxifen-resistant and Y537S ERα-expressing breast cancer cells.
    Cellular oncology (Dordrecht), 2018, Volume: 41, Issue:6

    Topics: Antineoplastic Agents; Breast Neoplasms; Cell Proliferation; Computer Simulation; Down-Regulation; D

2018
Frequency of Immune Cell Subtypes in Peripheral Blood Correlates With Outcome for Patients With Metastatic Breast Cancer Treated With High-Dose Chemotherapy.
    Clinical breast cancer, 2019, Volume: 19, Issue:6

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; CD8-Positive T

2019
Is there an optimal treatment sequencing strategy for metastatic castration-resistant prostate cancer?
    Future oncology (London, England), 2013, Volume: 9, Issue:5

    Topics: Androgen Receptor Antagonists; Antineoplastic Agents; Docetaxel; Humans; Male; Mitoxantrone; Neoplas

2013
A Successfully Treated Metastatic Choriocarcinoma Coexistent With Pregnancy: A Case Report of a 4-Year Follow-Up.
    Medicine, 2016, Volume: 95, Issue:21

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cesarean Section; Choriocarcinoma; Cyclophosp

2016
Constructing a conceptual framework of patient-reported outcomes for metastatic hormone-refractory prostate cancer.
    Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 2010, Volume: 13, Issue:5

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Anxiety; Area Under

2010
Schedule treatment design and quantitative in vitro evaluation of chemotherapeutic combinations for metastatic prostate cancer therapy.
    Cancer chemotherapy and pharmacology, 2011, Volume: 67, Issue:2

    Topics: Antineoplastic Agents; Benzamides; Cell Line, Tumor; Cell Proliferation; Ciprofloxacin; Dose-Respons

2011
[Hormone-refractory metastatic prostate carcinoma -- combination improves survival].
    Aktuelle Urologie, 2005, Volume: 36, Issue:5

    Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antine

2005
Tamoxifen versus tamoxifen + mitoxantrone treatment in metastatic breast cancer.
    Journal of chemotherapy (Florence, Italy), 1989, Volume: 1, Issue:4 Suppl

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Controlled Clinical T

1989
Mitoxantrone-related acute myeloblastic leukaemia in a patient with metastatic hormone-refractory prostate cancer.
    Anti-cancer drugs, 2007, Volume: 18, Issue:2

    Topics: Androgens; Antimetabolites, Antineoplastic; Antineoplastic Agents; Cytarabine; Humans; In Situ Hybri

2007
[A case of recurrent renal cell carcinoma which recurred after fourth surgical resection and survived for about 2 years by medroxyporgesterone acetate administration].
    Hinyokika kiyo. Acta urologica Japonica, 2007, Volume: 53, Issue:9

    Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Ce

2007
The postchemotherapy PSA surge syndrome.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2008, Volume: 19, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents; Antineo

2008
Mitoxantrone as first-line chemotherapy for advanced breast cancer: results of a European collaborative study.
    Seminars in oncology, 1984, Volume: 11, Issue:3 Suppl 1

    Topics: Adult; Aged; Anthraquinones; Breast Neoplasms; Drug Administration Schedule; Female; Humans; Injecti

1984
Phase II studies of mitoxantrone (dihydroxyanthracenedione) in the treatment of advanced colorectal carcinoma.
    American journal of clinical oncology, 1984, Volume: 7, Issue:5

    Topics: Anthraquinones; Antineoplastic Agents; Colonic Neoplasms; Drug Evaluation; Humans; Mitoxantrone; Neo

1984
Phase II study of mitoxantrone in advanced breast cancer: an Eastern Cooperative Oncology Group pilot study.
    Cancer treatment reports, 1984, Volume: 68, Issue:12

    Topics: Adult; Aged; Anthraquinones; Antineoplastic Agents; Breast Neoplasms; Drug Evaluation; Female; Human

1984
Combination chemotherapy with cyclophosphamide, mitoxantrone and 5-fluorouracil in patients with metastatic breast cancer.
    Cancer treatment reviews, 1983, Volume: 10 Suppl B

    Topics: Adult; Aged; Anthraquinones; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclo

1983
Mitoxantrone in advanced breast cancer: a phase II trial of the Southwest Oncology Group.
    Investigational new drugs, 1983, Volume: 1, Issue:2

    Topics: Adult; Aged; Anthraquinones; Antineoplastic Agents; Bone Marrow; Breast Neoplasms; Drug Evaluation;

1983
Phase II evaluation of dihydroxyanthracenedione (DHAD, NSC 301739) in patients with metastatic colorectal cancer.
    American journal of clinical oncology, 1983, Volume: 6, Issue:1

    Topics: Adult; Aged; Anthraquinones; Antineoplastic Agents; Bone Marrow; Colonic Neoplasms; Drug Evaluation;

1983
Phase II evaluation of dihydroxyanthracenedione (DHAD, NSC 301739) in patients with upper gastrointestinal tumors. A preliminary report.
    American journal of clinical oncology, 1983, Volume: 6, Issue:4

    Topics: Adult; Aged; Anthraquinones; Antineoplastic Agents; Drug Evaluation; Female; Humans; Leukocyte Count

1983
Potential cardiotoxicity with mitoxantrone.
    Cancer treatment reports, 1982, Volume: 66, Issue:8

    Topics: Adult; Aged; Anthraquinones; Antineoplastic Agents; Breast Neoplasms; Drug Evaluation; Female; Heart

1982
Dihydroxyanthracenedione: a promising new drug in the treatment of metastatic breast cancer.
    Annals of internal medicine, 1981, Volume: 95, Issue:6

    Topics: Adult; Aged; Agranulocytosis; Anthracenes; Antineoplastic Agents; Breast Neoplasms; Doxorubicin; Dru

1981
Mitoxantrone, vincristine, and 5-fluorouracil with leucovorin modulation as induction chemotherapy prior to high-dose intensification in metastatic breast cancer.
    Breast cancer research and treatment, 1993, Volume: 28, Issue:3

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dose-Response Relationship,

1993
Multiple cycles of high dose chemotherapy supported by hematopoietic progenitor cells as treatment for patients with advanced malignancies.
    Cancer, 1995, Sep-01, Volume: 76, Issue:5

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; Breast Neoplasms; Cyclopho

1995
Risk stratification for high-dose chemotherapy in metastatic breast cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1996, Volume: 14, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Female; Humans;

1996
[High-dose chemotherapy with four drugs and peripheral blood progenitor cell autologous transplantation in disseminated breast cancer].
    Medicina clinica, 1997, Dec-06, Volume: 109, Issue:20

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Cyclophosphami

1997
Successful treatment with mitoxantrone chemotherapy of acute disseminated intravascular coagulation due to metastatic androgen independent prostate cancer.
    The Journal of urology, 2000, Volume: 163, Issue:1

    Topics: Acute Disease; Aged; Aged, 80 and over; Androgens; Disseminated Intravascular Coagulation; Humans; M

2000
[Value of mitoxantrone in metastatic hormone-resistant prostate cancer].
    Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie, 2002, Volume: 12, Issue:1

    Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents; Drug Resistance, Neoplasm; Hum

2002
[Role of mitoxantrone in the treatment of hormone-independent metastatic cancer of the prostate].
    Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie, 2002, Volume: 12, Issue:1 Suppl 2

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Humans; Male; Mitoxantrone; N

2002
Mitoxantrone for advanced breast cancer.
    The Journal of the Association of Physicians of India, 1992, Volume: 40, Issue:4

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dose-Resp

1992
Mitoxantrone as a single agent in pretreated metastatic breast cancer: effects on T lymphocyte subsets and their relation to clinical response.
    Tumori, 1991, Jun-30, Volume: 77, Issue:3

    Topics: Adult; Aged; Breast Neoplasms; Female; Humans; Middle Aged; Mitoxantrone; Neoplasm Metastasis; T-Lym

1991
Mitoxantrone as second-line single agent in metastatic breast cancer.
    Oncology, 1991, Volume: 48, Issue:4

    Topics: Breast Neoplasms; Female; Heart; Heart Function Tests; Humans; Infusions, Intravenous; Menopause; Mi

1991
Intensive chemotherapy with cisplatin, mitoxantrone, methotrexate and vincristine in metastatic breast cancer.
    Journal of chemotherapy (Florence, Italy), 1991, Volume: 3, Issue:3

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Cisplatin; Femal

1991
A phase II study of mitoxantrone, etoposide, and thiotepa with autologous marrow support for patients with relapsed breast cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1990, Volume: 8, Issue:11

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Brea

1990
Anthracycline-carboplatin combination in metastatic breast cancer.
    Journal of cancer research and clinical oncology, 1990, Volume: 116, Issue:1

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Epirubicin; Fem

1990
Mitoxantrone, methotrexate and chlorambucil in metastatic breast cancer, a combination with relatively low subjective toxicity.
    The Netherlands journal of medicine, 1990, Volume: 36, Issue:1-2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Ch

1990
Mitomycin and mitoxantrone in previously treated patients with advanced breast cancer.
    Cancer treatment reports, 1987, Volume: 71, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Heart Diseases; Hematologic Diseas

1987
Mitoxantrone therapy of advanced adenocarcinoma of the endometrium. A phase II trial.
    Onkologie, 1989, Volume: 12, Issue:2

    Topics: Adenocarcinoma; Aged; Drug Evaluation; Female; Follow-Up Studies; Humans; Middle Aged; Mitoxantrone;

1989
Phase II evaluation of mitoxantrone in advanced non anaplastic thyroid cancer.
    Bulletin du cancer, 1989, Volume: 76, Issue:4

    Topics: Adult; Aged; Drug Evaluation; Female; Humans; Male; Middle Aged; Mitoxantrone; Neoplasm Metastasis;

1989
[Prolonged remissions induced by the combination vindesine, mitoxantrone, mitomycine C in metastatic breast cancers].
    Presse medicale (Paris, France : 1983), 1987, Apr-11, Volume: 16, Issue:13

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Middl

1987
Mitoxantrone, cyclophosphamide, and fluorouracil in metastatic breast cancer unresponsive to hormonal therapy.
    Cancer, 1987, Jun-15, Volume: 59, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Flu

1987
Long duration of response with vindesine-mitoxantrone-mitomycin (VMMc) combination chemotherapy in metastatic breast cancer: a pilot phase II study.
    Cancer treatment reports, 1987, Volume: 71, Issue:9

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Evaluation; Fema

1987
Use of mitoxantrone-based combination chemotherapy regimens as first-line treatment for advanced breast cancer.
    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 1987, Oct-03, Volume: 72, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Drug Administrat

1987
Mitoxantrone salvage in heavily pretreated advanced breast cancer.
    Progress in clinical and biological research, 1987, Volume: 248

    Topics: Aged; Aged, 80 and over; Breast Neoplasms; Combined Modality Therapy; Drug Resistance; Female; Human

1987
[Phase II study of mitoxantrone in advanced breast cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1986, Volume: 13, Issue:5

    Topics: Adult; Aged; Anthraquinones; Antineoplastic Agents; Breast Neoplasms; Drug Administration Schedule;

1986
First-line mitoxantrone chemotherapy for advanced breast cancer.
    Cancer treatment reports, 1986, Volume: 70, Issue:8

    Topics: Adult; Aged; Anthraquinones; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols;

1986
Mitoxantrone for carcinoma of the endometrium: a phase II trial of the Gynecologic Oncology Group.
    Cancer treatment reports, 1987, Volume: 71, Issue:2

    Topics: Adult; Aged; Drug Evaluation; Female; Humans; Middle Aged; Mitoxantrone; Neoplasm Metastasis; Uterin

1987
[Mitoxantrone in a combination regimen in advanced breast cancer].
    Wiener medizinische Wochenschrift (1946), 1985, Dec-31, Volume: 135, Issue:23-24

    Topics: Anthraquinones; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neopla

1985